Antibodies targeting B cell receptors of chronic lymphocytic leukemia and uses thereof
Through the specific antibody and nucleic acid sequence encoding against IGLV3-21R110, the problem of insufficient effectiveness of existing CLL treatment methods in IGLV3-21R110 positive patients is solved, and efficient killing and side effects on CLL cells are achieved, providing a targeted CLL Accurate treatment plan.
Patent Information
- Application Number
- CN202380033174.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-10
- Filing Date
- 2023-02-09
- Publication Date
- 2024-11-19
AI Technical Summary
Existing treatments for chronic lymphocytic leukemia (CLL) are not effective in patients with IGLV3-21R110 positive and are often accompanied by side effects, such as low blood cell count and high risk of infection.
A specific antibody against BCR containing IGLV3-21R110 was developed to kill malignant B cells by targeting these antibodies, encode antibodies using specific nucleic acid sequences, and in combination with pharmaceutical compositions and kits, to provide therapeutic regimens against CLL.
This antibody can selectively kill IGLV3-21R110-positive CLL cells, reduce side effects, improve treatment effect, and identify CLL cells through diagnostic methods, providing a more accurate treatment plan.
Smart Images

Figure BDA0005075763570000421 
Figure BDA0005075763570000431 
Figure BDA0005075763570000451
Abstract
Description
Technical Field
[0001] The present invention provides antibodies for treating chronic lymphocytic leukemia (CLL). These antibodies target the immunoglobulin lambda variable region 3-21 (IGLV3-21) with the R110 mutation. R110 ) is characterized by the B cell receptor (BCR) of CLL cells.
[0002] The present invention also provides a nucleic acid sequence encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition and a kit with instructions for use. Background Art
[0003] Antibody therapeutics have proven to be very effective agents for the treatment of leukemias and lymphomas arising from malignant transformation of B-lineage cells. Since the approval of monoclonal antibodies such as Rituximab, the response rates, long-term outcomes, and quality of life of patients with CLL have improved significantly.
[0004] CLL is a heterogeneous, B-lymphocyte-derived malignancy caused by the clonal proliferation of the CD5-positive subpopulation of B lymphocytes, which gradually accumulates in the bone marrow, lymph nodes, peripheral blood, and spleen (Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995; 333: 1052-1057). The disease is the most common type of leukemia in Western countries and usually occurs in elderly patients. Compared with women, the risk of CLL in men is twice that of women (Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukemia. Nat Rev Dis Primers (2017) 3: 1-12).
[0005] As reviewed by Burger and Chiorazzi, clinical and biological evidence has indicated that the BCR is one of the major factors in the clonal selection and survival of CLL cells (Burger JA, Chiorazzi NB cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592-601).
[0006] BCR is a multiprotein structure, which is composed of non-covalently associated antigen binding subunits and signal transduction subunits. The antigen binding subunit is composed of membrane immunoglobulins, which include two identical heavy chains and two identical light chains, each light chain has a constant domain, and each heavy chain has three constant domains. Each heavy chain associates with the light chain to form an antigen binding site. Each light chain and each heavy chain include variable domains that form an antigen binding site. The genes of the immunoglobulins encoded in Igh, Igl and Igk loci include a large amount of V (variable), D (diversity) and J (connection) gene segments (Gene Section) upstream of one or more constant exons. In developing B cells, immunoglobulin gene rearrangement randomly assembles V, D and J gene segments (GeneSegment) in the Igh locus to produce complete V exons, and randomly assembles V and J gene segments in Igk or Igl loci. Through combinatorial joining of gene segments, junctional diversity and random heavy and light chain pairing, each individual B cell progenitor produces its own and almost unique antigen-binding subunit, whose antigen-binding affinity can be further improved by somatic hypermutation (SHM).
[0007] The BCR signal transduction part is composed of a disulfide-linked heterodimer of Igα and Igβ (CD79a / CD79b) proteins. Igα and Igβ each contain a single immunoreceptor tyrosine-based activation motif (ITAM) in their cytoplasmic tails, which initiates signal transduction after BCR aggregation after antigen binding (Flaswinkel, H., Reth, M., 1994. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J. 13, 83–89).
[0008] Antigen binding rapidly activates the Src family kinase Lyn, leading to phosphorylation of Igα / Igβ. This triggers the formation of a large signaling complex (Signaling Complex) composed of BCR, various tyrosine kinases, adapter proteins and signal transduction enzymes on the cytoplasmic side of the membrane. Proximal BCR signaling is mediated by protein tyrosine kinase Syk (spleen tyrosine kinase), which is recruited to the phosphorylated ITAM of Igα and Igβ, and the association of Syk with the adapter protein SLP65 and its downstream signal transduction enzymes Bruton's Tyrosine Kinase (BTK) and phospholipase Cγ2 (PLCγ2) leads to the propagation of the signal. Signaling of the signaling complex activates downstream pathways, including calcium mobilization, phosphoinositide 3-kinase (PI3K), nuclear factor-κB (NF-κB), nuclear factor of activated T cells (NF-AT), mitogen-activated protein kinase (MAPK), and rat sarcoma (RAS) signaling pathways (Burger JA and Chiorazzi N, 2013, sa).
[0009] Chronic activation of mature B cells through the B cell receptor has been shown to be a key process in the formation and development of CLL (Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham GB-cell receptor signaling in chronic lymphocytic leukemia Blood. 2011; 118: 4313-4320). This is also consistent with a study using the EBV protein LMP2A as a constitutively active BCR alternative, which showed that the development of the mouse B1 subset depends on strong and persistent BCR stimulation (Casola S, Otipoby KI, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol 2004; 5: 317–27). In addition, due to the interaction of two adjacent BCRs on the cell, primary CLL B cell antigen-independent autonomous signaling has been identified as a key driver of CLL development, resulting in increased tyrosine phosphorylation of BCR proximal signaling molecules, leading to cyclic signaling and Ca 2+Mobilization is increased (Dühren-von Minden M et al. Chronic lymphocyticleukemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012; 489: 309-313).
[0010] There is ample evidence that protein kinase Syk is constitutively phosphorylated by sustained BCR signaling, and multiple studies have revealed that other key molecules in the downstream signaling pathways involved in BCR in normal B cells (such as PKC, phosphoinositide 3-kinase, and mitogen-activated protein kinase p38) are also constitutively activated in B-CLL cells, leading to deregulation of the activity or expression of multiple pro-survival molecules and deregulation of downstream pathways (Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009; 23: 686–697. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C et al. Constitutively activated phosphatidylinositol-3kinase(PI-3K) is involved in the defect of apoptosis in B-CLL:association with protein kinase Cdelta.Blood 2002;100:3741–3748.PlateJM.PI3-kinase regulates survival ofchronic lymphocytic leukemia B-cells by preventing caspase 8activation.LeukLymphoma 2004;45:1519–1529. Sainz-Perez A, Gary-Gouy H, Portier A, Davi F, Merle-Beral H, Galanaud P et al. High Mda-7expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocyticleukemia. Leukemia 2006;20:498–504).
[0011] It has been demonstrated that constitutively activated signaling pathways, such as NF-kB or PI3K / AKT, lead to the transcription and overexpression of key anti-apoptotic proteins, in particular B-cell lymphoma 2 (Bcl-2) and several members of the inhibitor of apoptosis protein (IAP) family (Loeder S et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 2009; 69: 8977-8986). It is well recognized that, in addition to Bcl-2 itself, Mcl-1 is also a key factor in impaired apoptosis in CLL cells, and BCR signaling has been reported to upregulate Mcl-1 expression through the PI3K / AKT pathway (Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov DG. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocyticleukemia B cells. Blood. 2005; 105: 4820-4827).
[0012] Different aspects of the BCR have been recognized to identify the main CLL disease subtypes. For example, the level of somatic hypermutation within the variable region of the BCR immunoglobulin heavy chain (IGHV) has been used as a prognostic marker for decades. CLL patients with mutated IGHV genes (M-CLL) (i.e., showing less than 98% IGHV gene identity with their closest germline) generally have a slower disease progression than CLL patients with unmutated IGHV genes (with germline identity equal to or greater than 98%) (U-CLL). However, exceptions to this rule have been observed, and their mutated IGHV gene status is not associated with a certain disease process. For example, cases using the IGHV3-21 gene, despite mostly expressing mutated BCRs, have one of the worst clinical outcomes. A different approach, but also determined by IGHV, leads to the classification of approximately 30% of CLL cases into important subgroups with different prognoses, each with highly homogeneous biological characteristics, clinical manifestations and outcomes. This classification is based on the observation that in mutated and unmutated cases, there are stereotyped BCRs carrying closely homologous heavy chain complementary determining region 3 (H-CDR3) sequences. According to this approach, CLL cases characterized by mutated IGHV3-21 can be assigned to the so-called subgroup #2 (Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenic implications and clinical correlations. Blood. 2007; 109(1): 259-270; Agathangelidis A., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: Amolecular classification with implications for targeted therapies. Blood. 2012; 119: 4467–4475).
[0013] Notably, it was consistently observed that the use of IGHV3-21 according to subgroup #2 was associated with the expression of immunoglobulin lambda variable region 3-21 chains and amino acid 110 in the light chain (IGLV3-21 R110 ) is associated with the acquired substitution of glycine by arginine. R110The reason for the arginine at position 110 of the BCR is a single G>C substitution at the splice site between the immunoglobulin λJ and constant genes. It has been identified that the presence of R110 together with the germline-encoded lysine 16 (K16) in one BCR and aspartates (D) 50 and 52 in the tyrosine-aspartate-serine-aspartate (YDSD) motif of the adjacent BCR enables BCR-BCR interactions, thereby triggering cell-autonomous signaling ( Figure 6 and Figure 7 ; Minici, C. et al., Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukemia, Nature Comm. 2017; 8:15746).
[0014] During the epigenetic, genomic, and transcriptomic characterization of a large cohort of CLL patients focused on the BCR light chain, it became apparent that approximately 60% of the IGLV3-21 R110 The case carried a non-stereotyped BCR, emphasizing that subgroup #2 was only based on IGLV3-21 R110 Characterized by a small subgroup of CLL (Stamatopoulos B, Smith T, Crompot E, et al. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study. Clin CancerRes. 2018; 24(20): 5048-5057. Nadeu F, Royo R, Clot G, et al. al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia within termediate epigenetics. Blood. 2021; 137(21):2935–2946).
[0015] Among the four alleles of the IGLV3-21 gene that have been identified in humans, allele IGLV3-21*01 (IMGT / LIGM-DB, acession No. X71966) and IGLV3-21*04(IMGT / LIGM-DB,acession No. AC279208 ) encodes the prerequisite K16 as well as D50 and D52, the last two of which are incorporated into the motif that, in most cases studied, is included in IGLV3-21 R110 The tyrosine at position 49 and the serine at position 51 (exemplary IGLV3-21 R110 , see Figure 7 ). However, in IGLV3-21 R110 Functionally equivalent variations in this motif, such as substitution of phenylalanine for tyrosine or threonine for serine, have also been observed in CLL patients (Nadeu et al. 2021, sa; for variants, see Figure 7 Interestingly, alleles IGLV3-21*01 and IGLV3-21*04 were significantly underexpressed in B cells of healthy donors, whereas all IGLV3-21 genes in patients studied by different groups could be assigned to either allele IGLV3-21*01 or allele IGLV3-21*04, suggesting that these alleles are essential for IGLV3-21. R110 It may be mechanistically required for the development of associated CLL.
[0016] IGLV3-21 R110 The CLL subgroup (for which the name subgroup #2L has been proposed) is associated with a very aggressive disease course. R110 Poor outcome in CLL cases is independent of IGHV mutation status or the nature of the heavy chain. R110 , and are related to different heavy chains such as IGHV1-18, IGHV3-53 or IGHV3-64 (Nadeu et al. 2021, supra), so IGLV3-21 R110 We define a group of CLL that is neither restricted to conventional subgroup classifications based on empirically defined epigenetic stereotypes nor to IGHV mutation status. Furthermore, the important role of R110 as a CLL driver mutation has been confirmed by site-specific mutagenesis experiments, which revealed that IGLV3-21 R110 To IGLV3-21 G110 Reversal of BCR activation leads to loss of BCR autonomous signaling ability (Stamatopoulos B, Smith T, Crompot E, et al. 2018, sa).
[0017] The time to first treatment (TTFT) and overall survival (OS) were compared with the presence of IGLV3-21 R110 The correlation study of BCR showed that with non-IGLV3-21 R110 Compared with CLL patients, those expressing IGLV3-21 R110 This emphasizes that IGLV3-21 R110 There is a rapid demand for therapy in positive patients (Nadeu F et al. 2021; sa).
[0018] CLL in these patients is usually treated with chemotherapy drugs, such as Idelalisib and Ibrutinib, both as single agents and in combination with other drugs. Idelalisib is an inhibitor of the hematopoietic cell-restricted delta isoform of PI3K, which promotes apoptosis of primary CLL cells (Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118: 3603-3612). Ibrutinib is an inhibitor of BTK, which induces apoptosis of B cell lymphoma and CLL cells (Hermann SE, Gordon AL, Hertlein E, et al. Brutontyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117: 6287-6296). Newer therapies increasingly use monoclonal antibodies, such as alemtuzumab, which acts as a CD52 antibody, or obinutuzumab, rituximab, and ofatumumab, which target the cell surface B lineage-restricted antigen CD-20. By using these antibodies, the remission time can be extended by about 10 months. However, the prior art therapies for treatment are often very stressful for patients, because the drug targets are critical for the survival of both normal B cells and malignant B cells, and low blood cell counts, including low levels of certain white blood cells (neutropenia) are common side effects. In addition, with regard to chemotherapeutic drugs, it is reported that high infection risk, latent infection, and off-target effects on the immune system are additional side effects. In general, it can be concluded that the adverse side effects of the therapy and the generally insufficient effects of such drugs lead to high mortality rates, because not only tumor cells, but also healthy cells of the immune system are destroyed.
[0019] Therefore, for IGLV3-21 R110 For patients with CLL who are positive for HER2, specific treatment options that are not associated with the above-mentioned side effects remain to be discovered.
[0020] About targeting IGLV3-21 R110 Current research on potential antibodies against the BCR is focused on the diagnosis of this specific subtype of CLL. As an example, Maity et al. described the use of anti-IGLV3-21 R110 Immunophenotyping study of antibodies as prognostic markers for CLL. R110 The antibodies were disclosed as IgG2a and Igκ antibodies (Maity PC, Bilal M, Koning MT, et al. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. PNAS. 2020; 117(8): 4320–4327).
[0021] The first step in opening up treatment options is disclosed in WO 2019 / 008129, which discloses antibodies that can be used to remove CLL cells from blood samples. The antibodies of WO 2019 / 008129 have been expressed as IgG antibodies in hybridoma cell lines that have left the mouse host. WO 2019 / 008129 only discloses the variable heavy chain domains and variable light chain domains corresponding to such antibodies.
[0022] WO 2019 / 008129 does not indicate that the antibodies disclosed therein are selective between healthy and diseased tissues, nor does it indicate that they have been used in vivo. Therefore, no therapeutic effect thereof is indicated. The antibodies of WO 2019 / 008129 are disclosed only by VH and VL, so any effect of the remaining constant regions of the antibodies disclosed therein remains unknown.
[0023] In summary, a therapeutic option, especially antibodies that are specific, selective and non-cross-reactive to other tissues, could make IGLV3-21 R110 Treatment options to improve the treatment of CLL in patients with positive disease remain unknown but are needed. Summary of the invention
[0024] The present invention solves the above-mentioned problem by providing the following antibodies in the first aspect, wherein the antibodies are: an antibody having a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2, or an antibody having a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12; or an antibody comprising any combination of a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 and a variable light chain having a sequence selected from the list consisting of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.
[0025] These antibodies bind specifically and selectively to IGLV3-21-containing tissues of CLL patients without cross-reacting with other tissues. R110 In the presence of IGLV3-21 that recognizes BCR, R110 This new antibody is also able to treat "subgroup #2 CLL", which is characterized by containing IGHV3-21 / IGLV3-21 R110 Combined BCR or containing IGLV3-21 R110 of any other CLL.
[0026] The provision of these antibodies leads to the second aspect of the present invention, which provides the use of the antibodies in the treatment of IGLV3-21 R110 Similarly, the second aspect of the present invention relates to the treatment of IGLV3-21 by administering a therapeutically active amount of the antibody. R110 Positive approach for patients with CLL.
[0027] This is IGLV3-21 R110 The first treatment option for CLL in patients with positive B cells that is able to selectively kill malignant B cells without the side effects associated with treatments offered by the prior art. More importantly, the presence of IGLV3-21 alone R110 The binding and killing of B cells characterized by the BCR makes such treatment independent of the requirement that such CLL belong to any previously identified CLL subgroup defined by a certain IGHV, which contains IGLV3-21 R110 BCR was identified as a CLL marker.
[0028] Without being bound by theory, it is believed that treatment with the antibodies of the present invention, in the absence of a costimulatory signal, activates IGLV3-21 through the BCR. R110Induce excessive activation of B cells. This ultimately leads to the induction of apoptosis in CLL cells bound by the antibody. Therefore, treatment with the antibodies of the present invention is highly selective for malignant B cells, and among them, IGLV3-21 R110 Positive B cells have an even higher selectivity.
[0029] In a third aspect, the present invention also relates to a DNA molecule (nucleic acid) encoding the antibody of the present invention. Therefore, the present invention also relates to a vector and a host cell containing the nucleic acid sequence of the present invention.
[0030] In a fourth aspect, the present invention also relates to the aforementioned antibodies for use in diagnosing CLL, wherein the CLL is characterized by expression of a gene containing IGLV3-21 by B cells. R110 Similarly, the fourth aspect of the present invention belongs to a method for diagnosing CLL, characterized in that the B cells express a BCR containing IGLV3-21 R110 The BCR of the present invention is detected by administering the antibodies to a sample of the patient's tissue or blood while coupling these antibodies to a detectable marker, or wherein another antibody is subsequently administered, which specifically binds to the antibody of the present invention and is coupled to a detectable marker.
[0031] definition
[0032] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the invention belongs. However, the following references can provide general definitions of many of the terms used in the present invention to those of ordinary skill in the art to which the invention belongs, and can be referenced and used, as long as such definitions are consistent with the meanings generally understood in the art. Such references include, but are not limited to, Singleton et al., Dictionary of Microbiology and Molecular Biology (2ded. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); Hale and Marham, The Harper Collins Dictionary of Biology (1991); and Lackie et al., The Dictionary of Cell & Molecular Biology (3ded. 1999); and Cellular and Molecular Immunology, eds. Abbas, Lichtman and Pober, 2nd ed., WB Saunders Company. Reference may be made to any additional technical resources available to one of ordinary skill in the art that provide definitions of terms used herein with meanings commonly understood in the art. For purposes of the present invention, the following terms are further defined.
[0033] As used herein and in the appended claims, the singular forms "a", "an", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "gene" refers to one or more genes and includes equivalents thereof known to those skilled in the art, and so forth.
[0034] "Autonomously active" BCR is a special type of permanently active BCR. While conventional activation is based on external antigens, autonomously active BCR is generated by its interaction with membrane structures on the same cell surface. For the clinical picture of CLL, it can be shown that autonomous activation triggers interactions between BCRs adjacent to each other on the same cell surface (e.g., M. Dühren-von Minden et.al; Nature 2012).
[0035] IGLV3-21 R110 It is the light chain variable region of BCR, which can initiate BCR-BCR interaction to induce autonomous active BCR. R110 is characterized by having a sequence identity of greater than 80% with the sequence as represented by SEQ ID NO 53, wherein in any case at position 110 of said sequence there is an arginine instead of a glycine.
[0036] As used herein, the term "antibody" is intended to refer to an immunoglobulin molecule, preferably composed of four polypeptide chains, i.e., two heavy (H) chains and two light (L) chains, which are usually interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated as VH in this article) and a heavy chain constant region. The heavy chain constant region can include, for example, three domains CH1, CH2 and CH3. Each light chain consists of a light chain variable region (abbreviated as VL in this article) and a light chain constant region. The light chain constant region consists of a domain (CL). The VH region and the VL region can be further subdivided into hypervariable regions known as complementary determining regions (CDRs), interspersed with more conservative regions known as framework regions (FRs). Each VH and VL is usually composed of three CDRs and up to four FRs arranged from the amino terminal to the carboxyl terminal, for example in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0037] As used herein, the term "complementarity determining region (CDR; e.g., CDR1, CDR2, and CDR3)" refers to the amino acid residues of an antibody variable domain whose presence is necessary for antigen binding. Each variable domain typically has three CDR regions, which are identified as CDR1, CDR2, and CDR3. The amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. ("Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991; "Kabat" numbering scheme), Chothia and Lesk (J Mol Biol 196:901-917 (1987)), and Lefranc et al. ("IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev. Comp. Immunol., 27:55-77, 2003; "IMGT" numbering scheme). Each complementary determining region comprises amino acid residues as defined by IMGT. In some cases, the complementary determining region may also comprise amino acids from a CDR region defined according to Kabat and / or a hypervariable loop according to the Chothia numbering system.
[0038] According to the amino acid sequence of the constant domain of their heavy chain, complete antibodies can be divided into different "classes". There are five main classes of complete antibodies: IgA, IgD, IgE, IgG and IgM, and several of these classes can be further divided into "subclasses" (isotypes), for example, IgG1, IgG2, IgG3, IgG4, IgA and IgA2. The heavy chain constant domains corresponding to different classes of antibodies are respectively referred to as [α], [δ], [ε], [γ] and [μ]. The subunit structure and three-dimensional configuration of different classes of immunoglobulins are well known.
[0039] As used herein, the term "antibody" is understood to also include antigen-binding fragments and variants thereof. Therefore, in the context of the present invention, any reference to an "antibody" is also a reference to an antigen-binding fragment and / or variants thereof, if not otherwise expressly stated, such as by specifying the full heavy chain or full light chain of the antibody that is combined to form the antibody.
[0040] "Antigen-binding fragment" is defined herein as a fragment of an antibody / immunoglobulin that retains an antigen-binding region (e.g., the variable region of IgG). Antigen-binding fragments of the present invention include Fab, Fab', F(ab')2, and Fv fragments; diabodies; single domain antibodies (DAb), linear antibodies; single-chain antibody molecules (scFv); and multispecific (such as bispecific and trispecific) antibodies formed from antibody fragments (CAK Borrebaeck, editor (1995) Antibody Engineering (Breakthroughs in Molecular Biology), Oxford University Press; R. Kontermann & S. Duebel, editors (2001) Antibody Engineering (Springer Laboratory Manual), Springer Verlag), Antibody Engineering (Springer Laboratory Manual), Springer Verlag). Except for "multispecific" or "multifunctional" antibodies, other antibodies are understood to have identical binding sites. F(ab')2 or Fab can be designed to minimize or completely remove the binding site in C H1 and C L Intermolecular disulfide interactions occur between domains.
[0041] The "antigen-binding region" of an antibody is typically found in one or more hypervariable regions of the antibody, e.g., CDR1, CDR2, and / or CDR3 regions; however, variable "framework" regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs.
[0042] A "variant" of an antibody or antigen-binding fragment contemplated by the present invention is a molecule in which the antibody or antigen-binding fragment retains its ability to bind to IGLV3-21. R110 binding activity.
[0043] A "humanized" antibody is defined herein as an antibody that: (i) is derived from a non-human source (e.g., a transgenic mouse with a heterologous immune system) and is based on human germline sequences; (ii) in which the amino acids of the framework regions of a non-human antibody are partially exchanged for human amino acid sequences by genetic engineering, or (iii) is CDR-grafted, in which the CDRs of the variable domains are derived from a non-human source, while one or more frameworks of the variable domains are of human origin, and the constant domains (if any) are of human origin.
[0044] A "chimeric" antibody is defined herein as an antibody in which the variable domains are derived from non-human sources and some or all of the constant domains are derived from human sources.
[0045] As used herein, the term "monoclonal" antibody refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies contained in the population are identical, except for possible mutations (e.g., naturally occurring mutations) that may be present in small amounts. Therefore, the term "monoclonal" represents the characteristics of an antibody, which is not a mixture of discrete antibodies. Contrary to the polyclonal antibody preparations that typically comprise different antibodies for different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed to a single determinant on an antigen. In addition to their specificity, the advantage of monoclonal antibody preparations is that they are generally not contaminated by other immunoglobulins. The term "monoclonal" should not be construed as requiring the production of the antibody by any ad hoc method. The term monoclonal antibody specifically includes mouse antibodies, chimeric antibodies, and humanized antibodies.
[0046] As used herein, an antibody that "specifically binds to an antigen of interest," "is specific for an antigen of interest," or "specifically recognizes an antigen of interest" is capable of distinguishing such antigen from one or more reference antigens, such as a tumor-associated polypeptide antigen target (here, IGLV3-21). R110 ). In its most general form, "specific binding", "specifically binds to", "is specific for", or "specifically recognizes" refers to the ability of an antibody to distinguish an antigen of interest from an unrelated antigen, such as determined according to one of the following methods. Such methods include, but are not limited to, flow cytometry, Western blot, ELISA test, RIA test, ECL test, IRMA test, immunohistology test, and peptide scanning.
[0047] "Binding affinity" or "affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule and its binding partner. Unless otherwise indicated, as used herein, "binding affinity" or "affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The dissociation rate constant K D Usually based on the equilibrium association (k a ) constant and dissociation rate (k d ) constant. The dissociation constant "K D"High affinity" is often used to describe the affinity between a molecule (such as an antibody) and its binding partner (such as an antigen), that is, how tightly a ligand binds to a specific protein. Ligand-protein affinity is influenced by non-covalent intermolecular interactions between the two molecules. The term "high affinity" refers to an antibody that binds to a protein with an affinity of less than or equal to 10 -9 M (monovalent affinity) affinity (KD) binding to IGLV3-21 R110 Positive CLL BCR. The antibody may have a significantly greater affinity for the target antigen than other unrelated molecules. Affinity can be measured by conventional methods known in the art, for example according to Example 5.
[0048] As used herein, the term "epitope" includes any protein determinant that is capable of specific binding to an immunoglobulin or T cell receptor. Epitope determinants are usually composed of chemically active surface groups of molecules, such as amino acids or sugar side chains or combinations thereof, and usually have specific three-dimensional structural characteristics as well as specific charge characteristics.
[0049] An "isolated" antibody is one that has been identified and separated from the cellular components that express it. Contaminating components of the cell are materials that interfere with the diagnostic or therapeutic use of the antibody and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the antibody is purified: (1) to greater than 95% antibody (by weight), as determined by, for example, the Lowry method, IN-Vis spectroscopy, or by SDS-capillary gel electrophoresis (e.g., on a Caliper LabChip GXII, GX 90, or Biorad Bioanalyzer device), and in further preferred embodiments, greater than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of the N-terminal or internal amino acid sequence, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver staining. Isolated naturally occurring antibodies include antibodies in situ within recombinant cells, since at least one component of the antibody's natural environment will not be present. However, typically, the isolated antibody will be prepared by at least one purification step.
[0050] The term immunoconjugate (interchangeably referred to as "antibody-drug conjugate" or "ADC") refers to an antibody coupled to one or more cytotoxic agents, such as chemotherapeutic agents, drugs, growth inhibitors, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof) or radioactive isotopes (i.e., radioconjugates). Immunoconjugates have been used in cancer therapy for local delivery of cytotoxic agents, drugs that kill or inhibit cell growth or proliferation (e.g., Liu et al., Proc Natl. Acad. Sci. (1996), 93, 8618-8623)). Immunoconjugates allow targeted delivery of drug moieties to tumors and intracellular accumulation therein, where systemic administration of uncoupled drugs may result in unacceptable levels of toxicity to normal cells and / or tissues. Toxins used for antibody-toxin conjugates include bacterial toxins (such as diphtheria toxin), plant toxins (such as ricin), and small molecule toxins (such as geldanamycin). These toxins may exert their cytotoxic effects through mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition.
[0051] The term "cancer" refers to the physiological condition or disease in which cells divide without control, resulting in unregulated cell growth. A "tumor" includes one or more cancer cells.
[0052] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which cells secrete Ig that binds to Fc receptors present on certain cytotoxic cells (e.g., NK cells, neutrophils, and macrophages). γ Receptor (Fc γ R), the cytotoxic cells are able to enable these cytotoxic effector cells to specifically bind to target cells bearing the antigen and subsequently kill the target cells, for example using cytotoxins.
[0053] "Complement dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to antibodies (of the appropriate subclass) that bind to their cognate antigens. To assess complement activation, a CDC assay such as that described by Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996) can be performed. For example, in U.S. Pat. No. 6,194,551B1 and WO 1999 / 51642, polypeptide variants having altered amino acid sequences of Fc regions (polypeptides having variant Fc regions) and increased or decreased Clq binding are described.
[0054] "Percent (%) Sequence Identity" is defined as, relative to a reference polynucleotide or polypeptide sequence, the percentage of nucleic acids or amino acid residues in a candidate sequence that are identical to those in a reference polynucleotide or polypeptide sequence, respectively, after alignment of the sequences and introduction of gaps (if necessary) to achieve maximum percent sequence identity. Conservative substitutions are not considered part of sequence identity. Preferably, gapless alignments are used. Alignments intended to determine percent amino acid sequence identity can be achieved in various ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, LALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequences.
[0055] Detailed description of the invention
[0056] First aspect of the invention - antibodies
[0057] The antibodies of the present invention are based on the discovery of a new mouse antibody that is specific for IGLV3-21 R110 The BCR of the subject has specific affinity and can bring therapeutic benefits to the subject. The antibodies and their beneficial properties that enable therapeutic activity will be described in more detail below.
[0058] The antibodies of the invention (which may be murine, humanized or chimeric) may be used in a number of contexts, which are more fully described herein.
[0059] According to the first aspect of the present invention, there is provided: an antibody having a heavy chain amino acid sequence of SEQ ID NO:1 and a light chain amino acid sequence of SEQ ID NO:2, or a heavy chain amino acid sequence of SEQ ID NO:11 and a light chain amino acid sequence of SEQ ID NO:12; or an antibody comprising any combination of a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO:15 and SEQ ID NO:20 and a variable light chain having a sequence selected from the list consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19.
[0060] These antibodies can be murine, humanized or chimeric, and they bind specifically to IGLV3-21 with high affinity. R110 -BCR.
[0061] As described above, these antibodies are believed to strongly activate the IGLV3-21R110 More specifically, these antibodies lead to strong phosphorylation of Syk, BTK, and PI3K in the short term, which induces apoptosis and ultimately inhibits tumor growth in vivo.
[0062] Preferred embodiments of the first aspect of the invention are further characterized in more detail in Tables 1 and 2 of the Examples.
[0063] Therefore, the antibody "mAb01-01" is a first preferred embodiment of the first aspect of the invention, characterized in that the heavy chain corresponds to SEQ ID NO:1 and the light chain corresponds to SEQ ID NO:2.
[0064] Therefore, the antibody "HCO-LC0" is a second preferred embodiment of the first aspect of the invention, characterized in that the heavy chain corresponds to SEQ ID NO:11 and the light chain corresponds to SEQ ID NO:12.
[0065] Therefore, the antibody "HC6-LC6" is a third preferred embodiment of the first aspect of the invention, characterized in that it has a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:16.
[0066] In said third preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
[0067] Therefore, the antibody "HC6-LC7" is a fourth preferred embodiment of the first aspect of the invention, characterized in that it has a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:17.
[0068] In said fourth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
[0069] Therefore, the antibody "HC6-LC8" is a fifth preferred embodiment of the first aspect of the invention, characterized in that the variable heavy chain region corresponds to SEQ ID NO:15 and the variable light chain region corresponds to SEQ ID NO:18.
[0070] In said fifth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
[0071] Therefore, the antibody "HC6-LC9" is a sixth preferred embodiment of the first aspect of the invention, characterized in that it has a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:19.
[0072] In said sixth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
[0073] Therefore, the antibody "HC7-LC6" is a seventh preferred embodiment of the first aspect of the invention, characterized in that the variable heavy chain region corresponds to SEQ ID NO:20 and the variable light chain region corresponds to SEQ ID NO:16.
[0074] In said seventh preferred embodiment of the first aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
[0075] Therefore, the antibody "HC7-LC7" is an eighth preferred embodiment of the first aspect of the invention, characterized in that the variable heavy chain region corresponds to SEQ ID NO:20 and the variable light chain region corresponds to SEQ ID NO:17.
[0076] In said eighth preferred embodiment of the first aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
[0077] Therefore, the antibody "HC7-LC8" is a ninth preferred embodiment of the first aspect of the invention, characterized in that the variable heavy chain region corresponds to SEQ ID NO:20 and the variable light chain region corresponds to SEQ ID NO:18.
[0078] In said ninth preferred embodiment of the first aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
[0079] Therefore, the antibody "HC7-LC9" is the tenth preferred embodiment of the first aspect of the invention, characterized in that the variable heavy chain region corresponds to SEQ ID NO:20 and the variable light chain region corresponds to SEQ ID NO:19.
[0080] In said tenth preferred embodiment of the first aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
[0081] The antibodies of this first aspect of the invention are not limited to the specific peptide sequences provided. Rather, the invention also includes variants. With reference to the present disclosure and conventionally available techniques and references, a skilled artisan will be able to prepare, test and utilize functional variants of the antibodies disclosed herein, while recognizing that functional variants having binding to IGLV3-21 R110 -BCR and thereby killing B cells fall within the scope of the present invention.
[0082] Variants can include, for example, antibodies with at least one altered complementary determining region (CDR) (hypervariable) and / or framework (FR) (variable) domain / site compared to the peptide sequences disclosed herein. To better illustrate this concept, a brief description of antibody structure is as follows.
[0083] Antibodies are composed of two peptide chains, each of which includes one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the latter consisting of four FR regions and three intervening CDRs (complementarity determining regions) in each case. The antigen binding site is formed by one or more CDRs, and the FR region provides a structural framework for the CDRs, and therefore plays an important role in antigen binding. By changing one or more amino acid residues in the CDR or FR region, technicians can usually generate mutant or diversified antibody sequences.
[0084] As an example, a skilled artisan can use the sequences of the antibodies provided herein (eg, the sequences of the antibodies of Table 1 and / or Table 2) to design peptide variants within the scope of the present invention.
[0085] In addition, by using an antibody of the first aspect of the present invention as a starting point for optimization, by diversifying one or more amino acid residues in the antibody, preferably one or more CDRs, and by screening the resulting set of antibody variants, variants can be obtained. Diversification can be accomplished by using a set of trinucleotide mutagenesis (TRIM) technology to synthesize DNA molecules (Virnekiis B. et al., Nucl. Acids Res. 1994, 22: 5600.). Antibodies include molecules with modifications / variations, including but not limited to, for example, modifications that lead to a changed half-life (e.g., modification of the Fc portion or the connection of another molecule such as PEG), a changed binding affinity or a changed ADCC or CDC activity.
[0086] Polypeptide variants can be prepared that retain the overall molecular structure of the antibody peptide sequence described herein. Considering the properties of the individual amino acids, the skilled person will recognize some reasonable substitutions. For example, based on the similarity of the polarity, charge, solubility, hydrophobicity, hydrophilicity and / or amphipathic properties of the residues involved, amino acid substitutions, i.e., "conservative substitutions," can be performed.
[0087] For example, (a) non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine; (c) positively charged (basic) amino acids include arginine, lysine and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions can generally be made in groups (a)-(d). In addition, glycine and proline can be substituted for each other based on their ability to disrupt the a-helix. Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more common in a-helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are more common in beta-pleated sheets. Glycine, serine, aspartic acid, asparagine and proline usually appear in turns. Some preferred substitutions can be made in the following groups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given the known genetic code and recombinant and synthetic DNA techniques, a skilled scientist can easily construct DNA encoding conservative amino acid variants.
[0088] The third to tenth preferred embodiments of the antibody according to the first aspect of the present invention may also comprise a variable heavy chain having at least 83.3%, 85%, 90%, 92%, 95% sequence identity with the variable heavy chain as represented by SEQ ID NO: 15, or at least 82.5%, 85%, 90%, 92%, 95% sequence identity with the variable heavy chain as represented by SEQ ID NO: 20.
[0089] The third to tenth preferred embodiments of the antibody according to the first aspect of the present invention may also comprise a variable light chain having at least 90%, 92%, or 95% sequence identity with the variable light chain as represented by SEQ ID NO: 16, or at least 87%, 90%, 92%, or 95% identity with the variable light chain as represented by SEQ ID NO: 17, or at least 80.5%, 85%, 90%, 92%, or 95% sequence identity with the variable light chain as represented by SEQ ID NO: 18, or at least 77.7%, 80%, 85%, 90%, 92%, or 95% sequence identity with the variable light chain as represented by SEQ ID NO: 19.
[0090] All preferred embodiments of the antibodies according to the first aspect of the present invention will combine: a variable heavy chain sequence comprising a sequence as represented by SEQ ID NO: 5 (H-CDR 1), SEQ ID NO: 6 (H-CDR 2) and SEQ ID NO: 7 (H-CDR 3), and a variable light chain sequence comprising a sequence as represented by SEQ ID NO: 8 (L-CDR 1), SEQ ID NO: 9 (L-CDR 2), SEQ ID NO: 10 (L-CDR3).
[0091] Therefore, preferred embodiments of the first aspect of the present invention include: an antibody combining a variable heavy chain sequence as represented by SEQ ID NO: 15 and a variable light chain comprising SEQ ID NO: 8 (L-CDR 1), SEQ ID NO: 9 (L-CDR 2), and SEQ ID NO: 10 (L-CDR 3), or an antibody combining a variable heavy chain sequence as represented by SEQ ID NO: 20 and a variable light chain comprising SEQ ID NO: 8 (L-CDR 1), SEQ ID NO: 9 (L-CDR 2), and SEQ ID NO: 10 (L-CDR 3), or an antibody combining a variable light chain sequence as represented by SEQ ID NO: 16 and a variable heavy chain comprising SEQ ID NO: 5 (H-CDR 1), SEQ ID NO: 6 (H-CDR 2), and SEQ ID NO: 7 (H-CDR 3), or an antibody combining a variable light chain sequence as represented by SEQ ID NO: 17 and a variable light chain comprising SEQ ID NO: 5 (H-CDR 1), SEQ ID NO: 6 (H-CDR 2), and SEQ ID NO: 7 (H-CDR 3). 2), an antibody comprising a variable heavy chain of SEQ ID NO: 7 (H-CDR 3), or an antibody comprising a variable light chain sequence as represented by SEQ ID NO: 18 and a variable heavy chain comprising SEQ ID NO: 5 (H-CDR 1), SEQ ID NO: 6 (H-CDR 2), and SEQ ID NO: 7 (H-CDR 3), or an antibody comprising a variable light chain sequence as represented by SEQ ID NO: 19 and a variable heavy chain comprising SEQ ID NO: 5 (H-CDR 1), SEQ ID NO: 6 (H-CDR 2), and SEQ ID NO: 7 (H-CDR 3).
[0092] According to the first aspect of the present invention, the antibodies are preferably any isotype IgG (eg, IgG1, IgG2, IgG3, IgG4). Their corresponding antigen binding fragments may be, for example, Fab, Fab', F(ab')2 or scFv.
[0093] Thus, an antibody fragment of the invention may be, or may comprise, an antigen binding region that functions in one or more of the ways described herein. For example, antibody HC6-LC6 (SEQ ID NO: 15 represents the VH chain, SEQ ID NO: 16 represents the VL chain) is expressed as humanized IgG1 (SEQ ID NO: 13 represents the heavy chain, SEQ ID NO: 14 represents the light chain), antibody HC6-LC7 (SEQ ID NO: 15 represents the VH chain, SEQ ID NO: 17 represents the VL chain) is expressed as humanized IgG1 (SEQ ID NO: 13 represents the heavy chain, SEQ ID NO: 22 represents the light chain), HC6-LC8 (SEQ ID NO: 15 represents the VH chain, SEQ ID NO: 18 represents the VL chain) is expressed as humanized IgG1 (SEQ ID NO: 13 represents the heavy chain, SEQ ID NO: 23 represents the light chain), antibody HC6-LC9 (SEQ ID NO: 15 represents the VH chain, SEQ ID NO: 19 represents the VL chain) is expressed as humanized IgG1 (SEQ ID NO: 13 represents the heavy chain, SEQ ID NO: 24 represents the light chain), antibody HC7-LC6 (SEQ ID NO: 15 represents the VH chain, SEQ ID NO: 17 represents the VL chain) is expressed as humanized IgG1 (SEQ ID NO: 13 represents the heavy chain, SEQ ID NO: 22 represents the light chain), SEQ ID NO: 20 represents the VH chain, SEQ ID NO: 16 represents the VL chain) is expressed as a humanized IgG1 (SEQ ID NO: 21 represents the heavy chain, SEQ ID NO: 14 represents the light chain), antibody HC7-LC7 (SEQ ID NO: 20 represents the VH chain, SEQ ID NO: 17 represents the VL chain) is expressed as a humanized IgG1 (SEQ ID NO: 21 represents the heavy chain, SEQ ID NO: 22 represents the light chain), HC7-LC8 (SEQ ID NO: 20 represents the VH chain, SEQ ID NO: 18 represents the VL chain) is expressed as a humanized IgG1 (SEQ ID NO: 21 represents the heavy chain, SEQ ID NO: 23 represents the light chain), and antibody HC7-LC9 (SEQ ID NO: 20 represents the VH chain, SEQ ID NO: 19 represents the VL chain) is expressed as a humanized IgG1 (SEQ ID NO: 21 represents the heavy chain, SEQ ID NO: 24 represents the light chain).
[0094] The most preferred antibodies of the first aspect of the invention are the antibodies of the second, third and seventh embodiments ("HC0-LC0", "HC6-LC6" and "HC7-LC6"), wherein the most preferred antibodies are the antibodies of the third and seventh embodiments ("HC6-LC6" and "HC7-LC6").
[0095] All of the above preferred embodiments of the first aspect of the invention are particularly advantageous because they have been shown to be effective in KD ~10 -10 M range, showing very high affinity, bringing about the beneficial aspect of the present invention, that is, they bind specifically, selectively and without cross-reaction with other tissues of CLL patients to the IGLV3-21 containing R110 BCR, thereby enabling selective killing of malignant B cells.
[0096] Regarding the most preferred antibodies ("HC0-LC0", "HC6-LC6" and "HC7-LC6"), these antibodies showed only about 1.2-2.1 10 -10 The highest affinity between M. The antibodies "HC6-LC6" and "HC7-LC6" according to the third and seventh preferred embodiments are additionally humanized, making them particularly suitable for therapeutic use due to their reduced immunogenicity.
[0097] All of the foregoing embodiments of the first aspect of the invention selectively bind to IGLV3-21 R110 In addition to the above-mentioned R110 In addition to the definitions provided, in generally preferred embodiments of this first aspect of the invention, the IGLV3-21 R110 Also characterized by having greater than 80% sequence identity to the sequence as represented by SEQ ID NO:53, wherein there is a lysine at position 16 and aspartic acid at positions 50 and 52. In a generally more preferred embodiment of this first aspect of the invention, there is a tyrosine or phenylalanine at position 49 and a serine or threonine at position 51. In a generally further more preferred embodiment of this first aspect of the invention, there is a tyrosine at position 49 and a serine at position 51.
[0098] In this first aspect of the invention, another embodiment provides antibodies that are modified and can deliver cytotoxic agents, immunotoxins, toxic groups or radioisotopes to cells expressing IGLV3-21R110-BCR to potentially further increase efficacy.
[0099] In some embodiments of this first aspect of the present invention, the antibody is separated. Separated biological components (such as nucleic acid molecules or proteins, such as antibodies) are components that have been substantially separated or purified from other biological components (such as other chromosomes and extrachromosomal DNA and RNA, proteins and organelles) in the cells of the organisms in which the components are naturally present. "Separated" nucleic acids and proteins include nucleic acids and proteins purified by standard purification methods described in, for example, Sambrook et al. 1989 (Sambrook, J. et al., (1989) sa) and Robert K.Scopes et al. 1994 (Protein Purification, -Principles and Practice, Springer Science and Business Media LLC). The term also encompasses nucleic acids and proteins prepared by recombinant expression in host cells, as well as chemically synthesized nucleic acids.
[0100] Second aspect of the invention - therapeutic use
[0101] The second aspect of the present invention relates to providing the use of the antibody of the first aspect of the present invention in treating CLL in IGLV3-21R110 positive patients. Similarly, the second aspect of the present invention relates to treating IGLV3-21R110 positive patients by administering a therapeutically active amount of the antibody of the first aspect of the present invention. R110 Positive approach for patients with CLL.
[0102] In a first preferred embodiment of this second aspect of the invention, therefore, the antibody is characterized by a heavy chain corresponding to SEQ ID NO:1 and a light chain corresponding to SEQ ID NO:2.
[0103] In a second preferred embodiment of this second aspect of the invention, the antibody is characterized by a heavy chain corresponding to SEQ ID NO:11 and a light chain corresponding to SEQ ID NO:12.
[0104] In a third preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:16.
[0105] In said third preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
[0106] In a fourth preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:17.
[0107] In said fourth preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
[0108] In a fifth preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:18.
[0109] In said fifth preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
[0110] In a sixth preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:19.
[0111] In said sixth preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
[0112] In a seventh preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:16.
[0113] In said seventh preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
[0114] In an eighth preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:17.
[0115] In said eighth preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
[0116] In a ninth preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:18.
[0117] In said ninth preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
[0118] In a tenth preferred embodiment of this second aspect of the invention, the antibody is characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:19.
[0119] In said tenth preferred embodiment, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
[0120] As mentioned in the context of the first aspect of the invention, all of the above embodiments of the second aspect of the invention rely on antibodies with very high affinity. All of these antibodies do not have a capture rate greater than about 3·10 at about 0.3 nm. -10 From this point of view alone, the second aspect of the present invention makes it possible to R110 Patients with CLL who are positive undergo highly selective treatment.
[0121] It has now been further demonstrated that these antibodies (see Figure 1 ) can selectively distinguish wild-type IGLV3-21 G110 Variant and malignant IGLV3-21 R110 variants, and treatment with these antibodies in xenograft mouse models (see Figure 5 and Example 9) lead to human IGLV3-21 R110 Significant depletion of positive B cells, thereby improving CLL.
[0122] Therefore, it has been surprisingly found that IGLV3-21 R110 Antibodies are effective in positive patients with CLL.
[0123] Furthermore, it can be demonstrated that the antibodies used in such treatments do not exhibit cross-reactivity with other tissues (see Figure 4 , Example 8).
[0124] Determining the effective dose of such antibodies is entirely within the capabilities of those skilled in the art. For any compound, a therapeutically effective dose can be preliminarily estimated in a cell culture assay (e.g., neoplastic cells) or in an animal model (typically mice, rabbits, dogs, pigs or monkeys). Animal models are also used to obtain desired concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration in humans.
[0125] A therapeutically effective dose refers to an amount of an antibody that improves the symptoms or condition to be treated. In the context of the present invention, the condition to be treated is clinically manifested CLL, which is caused by abnormal proliferation of B cells with autonomously active BCRs. More specifically, a second aspect of the present invention relates to clinically manifested CLL characterized by having a B cell containing IGLV3-21 R110 Abnormal proliferation of B cells with autonomously active BCRs.
[0126] All of the above embodiments of the second aspect of the present invention are suitable for IGLV3-21 R110 In addition to the above-mentioned treatment of IGLV3-21 R110 In addition to the definitions provided, the IGLV3-21 R110 In a generally preferred embodiment of this second aspect of the invention, it is further characterized by having greater than 80% sequence identity with a sequence as represented by SEQ ID NO 53, wherein a lysine is present at position 16 and aspartic acid is present at positions 50 and 52. In a generally more preferred embodiment of this first aspect of the invention, a tyrosine or phenylalanine is present at position 49 and a serine or threonine is present at position 51. In a generally further more preferred embodiment of this first aspect of the invention, a tyrosine is present at position 49 and a serine is present at position 51.
[0127] Thus, a therapeutically effective amount is a dose sufficient to deplete IGLV3-21 in the treatment area of the patient, either as a single dose or according to a multiple dose regimen. R110 The amount of antibody that is toxicologically tolerable is to inhibit CLL cells.
[0128] In a second aspect of the invention, for treating IGLV3-21 R110 Antibodies against CLL in positive patients are preferred, and the dosage of the antibodies used is 0.25-25 mg / kg 体重 , more preferably 1-20 mg / kg 体重 , most preferably greater than 7-15 mg / kg 体重 , and particularly preferably 8-12 mg / kg 体重 .
[0129] These doses are extremely low, resulting in a total drug amount to be administered hypothetically to an average human patient of about 80 kg not exceeding a particularly preferred range of 640-960 mg to achieve a strong depletion of malignant B cells.
[0130] The exact dosage is chosen by the individual physician based on the patient to be treated. The dosage is adjusted and administered to provide sufficient levels of the active moiety or to achieve the desired effect. However, the present invention has shown that in a xenograft mouse model, a dosage of no more than 0.3 mg / kg twice a week is already effective, while a strong depletion of malignant cells can be achieved at a dosage of 10 mg / kg (twice a week).
[0131] When administering antibody drugs according to the second aspect of the present invention, additional factors may also be considered, which may include the severity of the disease state, for example, the size and location of the tumor; the age, weight and sex of the patient and diet. Additional influencing factors for determining appropriate dosages may be drug combinations, reaction sensitivity and tolerance / response to therapy.
[0132] Furthermore, more than one administration may be performed, and the timing and frequency of administration may further affect the individual doses administered.
[0133] According to the second aspect of the present invention, the antibody can also be co-administered with a known drug. Therefore, they can be administered as the sole pharmaceutical agent, or in combination with one or more additional therapeutic agents, wherein the combination does not cause unacceptable side effects. This combination therapy includes: administering a single pharmaceutical dosage formulation, the formulation comprising an antibody according to the first aspect of the present invention and one or more additional therapeutic agents; and administering the antibody of the first aspect of the present invention and each additional therapeutic agent with its own separate pharmaceutical dosage formulation.
[0134] In the case of adopting a separate dosage preparation (Separate Dosage Formulation), according to a second aspect of the present invention, the treatment with one or more other therapeutic agents can be carried out at substantially the same time (e.g., simultaneously) or at a staggered time (e.g., sequentially) separated. In particular, the treatment according to the present invention can be fixedly combined with other antitumor agents or individually combined, and the antitumor agents such as alkylating agents, antimetabolites, antitumor agents of plant origin, hormone therapy agents, topoisomerase inhibitors, camptothecin derivatives, kinase inhibitors, targeted drugs, antibodies, interferons and / or biological response modifiers, anti-angiogenic compounds and other antitumor drugs can be carried out.
[0135] The antibodies of the invention may also be used in cancer treatment in combination with radiation therapy and / or surgical intervention.
[0136] Aspect 3 - Polynucleotides
[0137] The present invention also relates to a DNA molecule encoding the antibody of the first aspect of the invention.
[0138] The DNA molecules of the present invention are not limited to the sequences disclosed herein, but also include variants thereof. DNA variants in the present invention can be described by reference to their physical properties in hybridization. The technician will recognize that using nucleic acid hybridization techniques, DNA can be used to identify its complementary sequence, and because DNA is double-stranded, it can be used to identify its equivalent or homologue. It will also be recognized that hybridization can occur when less than 100% complementarity. However, it is assumed that under appropriately selected conditions, hybridization techniques can be used to distinguish DNA sequences based on the structural correlation of DNA sequences with specific probes. For guidance on such conditions, see Sambrook, J., Fritsch, EF and Maniatis, T. (1989) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, and Ausubel et al. 1995 (Ausubel, FM, Brent, R., Kingston, RE, Moore, DD, Sedman, JG, Smith, JA, & S1ruhl, K. eds. (1995). Current Protocols in Molecular Biology. New York: John Wiley and Sons).
[0139] The structural similarity between two polynucleotide sequences can be expressed as a function of the "stringency" of the conditions under which the two sequences will hybridize to each other. As used herein, the term "stringency" refers to the degree to which the conditions are unfavorable for hybridization. Strict conditions strongly discourage hybridization, and only the most structurally related molecules can hybridize to each other under such conditions. In contrast, non-strict conditions favor the hybridization of molecules that show a lower degree of structural relatedness. Therefore, hybridization stringency is directly related to the structural relationship of the two nucleic acid sequences. The following relationship is useful in correlating hybridization and relatedness (where Tm is the melting temperature of a nucleic acid duplex): aT m =69.3+0.41(G+C)% b. For every 1% increase in the number of mismatched base pairs, the T m Reduce by 1℃. c.(T m )μ2-(T m )μ1=18.5log 10 μ2 / μ1 where μ1 and μ2 are the ionic strengths of the two solutions.
[0140] Hybridization stringency is a function of many factors, including total DNA concentration, ionic strength, temperature, probe size, and the presence of agents that disrupt hydrogen bonds. Factors that promote hybridization include high DNA concentration, high ionic strength, low temperature, longer probe size, and the absence of agents that disrupt hydrogen bonds. Hybridization is typically performed in two stages: a "binding" stage and a "washing" stage.
[0141] Yet another class of DNA variants within the scope of the present invention can be described with reference to the products they encode.These functionally equivalent polynucleotides are characterized by the fact that, due to the degeneracy of the genetic code, they encode the same peptide sequences found in SEQ ID NOs: 1-24.
[0142] We recognize that variants of the DNA molecules provided herein can be constructed in several different ways. For example, they can be constructed as fully synthetic DNA. Methods for efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available. See Ausubel et al., Section 2.11, Supplement 21 (1993). Overlapping oligonucleotides can be synthesized and assembled in a manner first reported by Khorana et al. in J.Mol.Biol.72:209-217 (1971); see also Ausubel et al., supra, Section 8.2. The synthetic DNA is preferably designed to have convenient restriction sites at the 5' and 3' ends of the gene for cloning into a suitable vector.
[0143] As described, the method for producing variants is to start with one of the DNA disclosed herein and then perform site-directed mutagenesis. See Ausubel et al., supra, Chapter 8, Supplement 37 (1997). In a typical method, the target DNA is cloned into a single-stranded DNA phage vector. The single-stranded DNA is isolated and hybridized with an oligonucleotide containing the desired nucleotide changes. The complementary strand is synthesized, and the double-stranded phage is introduced into the host. Some of the resulting progeny will contain the desired mutants, which can be confirmed using DNA sequencing. In addition, various methods can be used to increase the possibility that the progeny phage becomes the desired mutant. These methods are well known to those skilled in the art, and the kit for producing such mutants is commercially available.
[0144] As with the first aspect of the invention, there are corresponding preferred embodiments of this third aspect of the invention.
[0145] In a first preferred embodiment of this third aspect of the invention, the present invention relates to a DNA molecule encoding the heavy chain of one of the preferred antibodies of the first aspect of the invention, said heavy chain being represented by any sequence selected from the list consisting of SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:33 and SEQ ID NO:38.
[0146] In a second preferred embodiment of this third aspect of the invention, the invention relates to a DNA molecule encoding the light chain of one of the preferred antibodies of the first aspect of the invention, said light chain being represented by any sequence selected from the list consisting of SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36 and SEQ ID NO:37.
[0147] The nucleic acids of the invention are suitable for the recombinant production of antibodies using standard vectors and host cells containing the nucleic acid sequences of the invention.
[0148] Aspect 4 - Diagnostic Methods
[0149] The antibodies of the present invention can be used to detect the expression of IGLV3-21 R110 The antibody of the present invention can be used to detect IGLV3-21 in various biological samples (including serum and tissue biopsy specimens). R110 CLL cells or shed cells expressing IGLV3-21 R110 In addition, the antibodies can be used in various imaging methods, such as 99 Tc (or other isotope)-conjugated antibodies for immunoscintigraphy. 111In-conjugated anti-PSMA antibodies The imaging protocol described can be used to detect pancreatic cancer or ovarian cancer (Sodee et al., Clin. Nuc. Med. 21: 759-766, 1997). Another detection method that can be used is positron emission tomography by coupling the antibodies of the invention to a suitable isotope (see Herzog et al., J. Nucl. Med. 34: 2222-2226, 1993).
[0150] Therefore, according to a fourth aspect, the present invention also relates to the aforementioned antibodies for use in diagnosing CLL (the CLL is characterized in that B cells have autonomous activity, contain IGLV3-21 R110 Similarly, the fourth aspect of the invention relates to a method for diagnosing CLL (the CLL is characterized by B cells having autonomous activity, containing IGLV3-21) by administering the antibody to a sample of a patient's tissue or blood. R110 The invention also provides a method for diagnosing subgroup 2 CLL by detecting BCR of the present invention, and thus also a method for diagnosing subgroup 2 CLL, while these antibodies are coupled to a detectable marker, or wherein an additional antibody that specifically binds to the antibody of the invention and is coupled to a detectable marker is subsequently administered.
[0151] In a first preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "mAb01-01", characterized by a heavy chain corresponding to SEQ ID NO:1 and a light chain corresponding to SEQ ID NO:2.
[0152] In a second preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HCO-LC0", characterized in that the heavy chain corresponds to SEQ ID NO:11 and the light chain corresponds to SEQ ID NO:12.
[0153] In a third preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HC6-LC6", characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:16.
[0154] In said third preferred embodiment of the fourth aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
[0155] In a fourth preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HC6-LC7", characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:17.
[0156] In said fourth preferred embodiment of the fourth aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
[0157] In a fifth preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HC6-LC8", characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:18.
[0158] In said fifth preferred embodiment of the fourth aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
[0159] In a sixth preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HC6-LC9", characterized by a variable heavy chain region corresponding to SEQ ID NO:15 and a variable light chain region corresponding to SEQ ID NO:19.
[0160] In said sixth preferred embodiment of the fourth aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
[0161] In a seventh preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HC7-LC6", characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:16.
[0162] In said seventh preferred embodiment of the fourth aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
[0163] In an eighth preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HC7-LC7", characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:17.
[0164] In said eighth preferred embodiment of the fourth aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
[0165] In a ninth preferred embodiment of this fourth aspect of the invention, the antibody for diagnosis is "HC7-LC8", characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:18.
[0166] In said ninth preferred embodiment of the fourth aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
[0167] In a tenth preferred embodiment of this fourth aspect of the invention, the antibody used for diagnosis is "HC7-LC9", characterized by a variable heavy chain region corresponding to SEQ ID NO:20 and a variable light chain region corresponding to SEQ ID NO:19.
[0168] In said tenth preferred embodiment of the fourth aspect of the present invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
[0169] Further aspects of the invention
[0170] The antibody of the first aspect of the present invention used in the second aspect of the present invention can be co-administered with known drugs. For example, the antibody can be co-administered with any conventional anti-B cell antibody.
[0171] Such combination therapy includes administration of a single pharmaceutical dosage formulation containing an antibody of the invention and one or more additional therapeutic agents, as well as administration of an antibody of the invention and each additional therapeutic agent in its own separate pharmaceutical dosage formulation. For example, an antibody of the invention and a therapeutic agent can be administered to a patient together in a single injection, or each agent can be administered in a separate dosage formulation.
[0172] In the case of using a single dose of the formulation, the antibody of the present invention and one or more additional therapeutic agents can be administered at substantially the same time (e.g., simultaneously) or at separate staggered times (e.g., sequentially). Specifically, the antibody of the present invention can be used in fixed combination or separately in combination with other anti-tumor agents, such as alkylating agents, antimetabolites, anti-tumor agents of plant origin, hormone therapeutic agents, topoisomerase inhibitors, camptothecin derivatives, kinase inhibitors, targeted drugs, antibodies, interferons and / or biological response modifiers, anti-angiogenic compounds and other anti-tumor drugs. In this regard, the following is a non-limiting list of examples of second agents that can be used in combination with the antibodies of the present invention:
[0173] Alkylating agents include, but are not limited to, nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, Thiotepa, Ranimustine, Nimustine, Temozolomide, Hexamethylmelamine, Apaziquone, Brostallicin, Bendamustine, Carmustine, Estramustine, Fotemustine, Glufosfamide, Mafosfamide, Bendamustine, and Dibromodulcitol; platinum-coordinated alkylating compounds include, but are not limited to, Cisplatin, Carboplatin, Etopoplatin, Lobaplatin, Nedaplatin, Oxaliplatin, and Satraplatin;
[0174] Antimetabolites include, but are not limited to, methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil alone or in combination with leucovorin, Tegafur, doxifluridine, Carmofur, cytarabine, cytarabine ocfosfate, enocitabine, gemcitabine, fludarabin, 5-azacitidine, capecitabine, cladribine, clofarabine, decitabine, eflornithine, ethynylcytidine, cytosine arabinoside, hydroxyurea, melphalan, nelarabine, nolatrexed, ocfosfite, disodium pemetrezol, Premetrexed), Pentostatin, Peli1rexol, Raltitrexed, Triapine, Trimetrexate, Adenosine, Vincristine, and Vinorelbine;
[0175] Hormonal therapeutic agents include, but are not limited to, Exemestane, Lupron, Anastrozole, Doxercalciferol, Fadrozole, Formestane, 11-β hydroxysteroid dehydrogenase I inhibitors, 17-α hydroxylase / 17,20 lyase inhibitors (such as Abiraterone Acetate), 5-α reductase inhibitors (such as Finasteride and Epristeride), antiestrogens (such as Tamoxifen Citrate), Citrate and Fulvestrant), Trelstar, Toremifene, Raloxifene, Lasofoxifene, Letrozole, anti-androgens such as Bicalutamide, Flutamide, Mifepristone, Nilutamide, Casodex, and anti-progestins and combinations thereof;
[0176] Antitumor substances of plant origin include, for example, those selected from mitotic inhibitors, for example, Epothilones (such as Sagopilone, Ixabepilone and Epothilone B), Vinblastine, Vinflunine, Docetaxel and Paclitaxel;
[0177] Cytotoxic topoisomerase inhibitors include, but are not limited to, Aclarubicin, Doxorubicin, Amonafide, Belotecan, Camptothecin, 10-Hydroxycamptothecin, 9-Aminocamptothecin, Diflomotecan, Irinotecan, Topotecan, Edotecarin, Epimbicin, Etoposide, Exatecan, Gimatecan, Lurtotecan, Mitoxantrone, Pirambicin, Pixantrone, Rubitecan, Sobuzoxane, Tafluposide, and combinations thereof;
[0178] Immunological drugs include interferons, such as interferon α, interferon α-2a, interferon α-2b, interferon β, interferon γ-1a and interferon γ-n1, and other immunopotentiators, such as L19-IL2 and other IL2 derivatives, Filgrastim, Lentinan, Sizofilan, TheraCys, Ubenimex, Aldesleukin, Alemtuzumab, BAM-002, Dacarbazine, Daclizumab, Denileukin, Gemtuzumab, Ozogamicin, Ibritumomab Tiuxetan Ibri1umomab, Imiquimod, Lenograstim, Lentinan, Corixa, Molgramostim, Sargramostim, Tasonermin, Tesileukin, Thymofasin, Tositumomab, Vimlizin, Epratuzumab, Mitumomab, Oregovomab, Pemtumomab, and Provenge;
[0179] Biological response modifiers are agents that alter the defense mechanisms or biological responses of living organisms such as tissue cell survival, growth or differentiation to render them anti-tumor active; such agents include, for example, Krestin, Lentinan, Sizoran, Picibanil, ProMune and Ubenimex.
[0180] Anti-angiogenic compounds include, but are not limited to, Acitretin, Aflibercept, Angiostatin, Aplidine, Asentar, Axitinib, Bevacizumab, Brivanib Alaninat, Cilengtide, Combretastatin, Endostatin, Fenretinide, Halofuginone, Pazopanib, Ranibizumab, Rebimastat, Recentin, Regorafenib, Removab, Revlimid, Sorafenib, Squalamine, Sunitinib, Telatinib, Thalidomide, Ukrain, Vatalanib, and Vitaxin;
[0181] Antibodies include, but are not limited to, Trastuzumab, Cetuximab, Bevacizumab, Rituximab, Ticilimumab, Ipilimumab, Lumiliximab, Catumaxomab, Atacicept, Oregovomab, and Alemtuzumab;
[0182] VEGF inhibitors, such as, for example, sorafenib, regorafenib, bevacizumab, sunitinib, cediranib (Recentin), axitinib, aflibercept, telatinib, brivanib alanine, vatalanib, pazopanib, and ranibizumab;
[0183] EGFR (HERI) inhibitors, such as, for example, Cetuximab, Panitumumab, Vectibix, Gefitinib, Erlotinib, and Zactima;
[0184] HER2 inhibitors, such as, for example, Lapatinib, Trastuzumab, and Pertuzumab;
[0185] mTOR inhibitors, such as, for example, Temsirolimus, Sirolimus / rapamycin, and Everolimus; c-Met inhibitors;
[0186] PI3K and AKT inhibitors;
[0187] CDK inhibitors, such as Roscovitine and Flavopiridol;
[0188] Spindle assembly checkpoint inhibitors and targeted mitotic agents, such as PLK inhibitors, Aurora kinase inhibitors (e.g., Hesperadin), checkpoint kinase inhibitors, and KSP inhibitors;
[0189] HDAC inhibitors, such as, for example, Panobinostat, Vorinostat, MS275, Belinostat, and LBH589;
[0190] HSP90 and HSP70 inhibitors;
[0191] Proteasome inhibitors, such as Bortezomib and Carfilzomib;
[0192] Serine / threonine kinase inhibitors, including MEK inhibitors and Raf inhibitors such as sorafenib;
[0193] Farnesyl transferase inhibitors, such as, for example, Tipifarnib;
[0194] Tyrosine kinase inhibitors, including, for example, dasatinib, nilotibib, regorafenib, bosutinib, sorafenib, bevacizumab, sunitinib, cediranib, axitinib, aflibercept, teletinib, imatinib mesylate, brivanib alanine, pazopanib, ranibizumab, vatalanib, cetuximab, panitumumab, vicaribinib, gefitinib, erlotinib, lapatinib, trastuzumab, pertuzumab, and c-Kit inhibitors;
[0195] Vitamin D receptor agonists;
[0196] Bcl-2 protein inhibitors, such as Obatoclax, Oblimersen Sodium, and Gossypol; Cluster of differentiation 20 receptor antagonists, such as, for example, Rituximab; Ribonucleotide reductase inhibitors, such as, for example, Gemcitabine;
[0197] Tumor necrosis apoptosis-inducing ligand receptor 1 agonists, such as, for example, Mapatumumab;
[0198] Serotonin receptor antagonists, such as, for example, rEV598, xaliprode, Palonosetron Hydrochloride, Granisetron, Zindol, and AB-1001;
[0199] Integrin inhibitors, including α5-β1 integrin inhibitors, such as, for example, E7820, JSM6425, Volociximab, and endostatin;
[0200] androgen receptor antagonists, including, for example, Nandrolone Decanoate, Fluoxymesterone, Android, Prost-aid, Andromustine, Bicalutamide, Flutamide, Alpcyproterone, Alpflutamide, Chlormadinone Acetate, Androcur, Tabi, Cyproterone Acetate, and Nilutamide;
[0201] Aromatase inhibitors, such as, for example, Anastrozole, Letrozole, Testolactone, Exemestane, Aminoglutethimide, and Formestane;
[0202] Matrix metalloproteinase inhibitors;
[0203] Other anticancer agents include, for example, alitretinoin, Ampligen, Atrasentan, Bexarotene, Bortezomib, Bosentan, Calcitriol, Exisulind, Fotemustine, Ibandronic Acid, Miltefosine, Mitoxantrone, I-asparaginase, Procarbazine, Dacarbazine, Hydroxyurea, Pegaspargase, Pentostatin, Tazaroten, Velcade, Gallium Nitrate, Canfosfamide, Darinaparsin, and Retinoic Acid.
[0204] In preferred embodiments, the antibodies of the invention may be used in combination with chemotherapy (ie, cytotoxic agents), anti-hormones, and / or targeted therapies such as kinase inhibitors, mTOR inhibitors, and angiogenesis inhibitors.
[0205] The antibody according to the first aspect of the invention may itself be modified in some cases. Thus, it may be, for example, an ADC (as defined above).
[0206] The antibodies of the invention may also be used in cancer treatment in combination with radiation therapy and / or surgical intervention.
[0207] The present invention also relates to a composition comprising an antibody according to any embodiment of the first aspect of the invention, which may be used analogously to the second aspect of the invention.
[0208] Thus, the present invention includes a pharmaceutical composition comprising an antibody according to the first aspect of the invention alone or in combination with at least one other agent and a pharmaceutically acceptable carrier or excipient.
[0209] The other agent may be, for example, a stabilizing compound, and such at least one other agent and the antibody according to the first aspect of the invention may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose and water.
[0210] The pharmaceutical composition of the present invention may be manufactured in a manner known in the art, such as by conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes.
[0211] A preferred pharmaceutical composition is made of lyophilized powder of the antibody according to the first aspect of the invention in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5-5.5, and mixed with a buffer before use.
[0212] After pharmaceutical compositions comprising antibodies of the invention formulated in an acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition.
[0213] Therefore, in a related aspect, the present invention also relates to such pharmaceutical compositions, which are used for IGLV3-21 R110 Likewise, the related aspects of the invention relate to treating IGLV3-21 by administering a therapeutically active amount of such a pharmaceutical composition. R110 Positive approach for patients with CLL.
[0214] Such administration is usually by parenteral administration. Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.
[0215] Preferred routes of administration are intravenous and intraarterial (directly to the tumor).
[0216] Pharmaceutical compositions for parenteral administration include aqueous solutions of the active compound. For injection, the pharmaceutical compositions of the present invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution or physiologically buffered saline. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran. In addition, the suspension of the active compound can be prepared as a suitable oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain a suitable stabilizer or an agent that increases the solubility of the compound to allow the preparation of a highly concentrated solution.
[0217] For topical or intranasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
[0218] Determine that the therapeutically effective amount of an antibody or a pharmaceutical composition comprising such an antibody depends to a great extent on the properties of specific patient characteristics, route of administration and the disease being treated. For example, in the publications of the International Conference on Harmonization and REMINGTON'S PHARMACEUTICAL SCIENCES, Chapter 27 and Chapter 28, 484-528 pages (18th edition, Alfonso R. Gennaro edited, Easton, Pa.: Mack Pub. Co., 1990), general guidelines can be found. More specifically, determine that the therapeutically effective amount will depend on factors such as the toxicity and efficacy of the drug. Toxicity can be determined using methods well known in the art and the methods found in the aforementioned references. Efficacy can be determined using the same guidelines.
[0219] The present invention further relates to pharmaceutical packaging and test kits, comprising one or more containers filled with one or more components of the above-mentioned compositions of the present invention. Associated with such containers may be a notice in a form prescribed by a governmental agency regulating the manufacture, use or sale of drugs or biological products, reflecting the approval of the agency for the manufacture, use or sale of products for human administration.
[0220] In another embodiment, the kit may include a DNA sequence encoding an antibody according to the third aspect of the present invention. Preferably, the DNA sequence encoding these antibodies is provided with a plasmid suitable for transfection into a host cell and expressed by the host cell. The plasmid may include a promoter (usually an inducible promoter) to regulate the expression of the DNA in the host cell. The plasmid may also include appropriate restriction sites to facilitate the insertion of other DNA sequences into the plasmid to produce various antibodies. The plasmid may also include many other elements to facilitate the cloning and expression of the encoded protein. Such elements are well known to those skilled in the art, and include, for example, selective markers, start codons, stop codons, etc.
[0221] Therefore, the present invention further relates to the above-mentioned packaging and kit, which comprises one or more containers filled with a pharmaceutical composition for treating IGLV3-21. R110 One or more components of the above-described composition of the present invention for a CLL-positive patient.
[0222] The preferred embodiments of the present invention are: A. An antibody having The heavy chain amino acid sequence represented by SEQ ID NO: 1 and the light chain amino acid sequence represented by SEQ ID NO: 2, or The heavy chain amino acid sequence of SEQ ID NO: 11 and the light chain amino acid sequence of SEQ ID NO: 12; or An antibody comprising any combination of a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 and a variable light chain having a sequence selected from the list of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19. B. The antibody according to embodiment A, characterized by a heavy chain corresponding to SEQ ID NO: 1 and a light chain corresponding to SEQ ID NO: 2. C. The antibody according to embodiment A, characterized by a heavy chain amino acid sequence of SEQ ID NO:11 and a light chain amino acid sequence of SEQ ID NO:12. D. The antibody according to embodiment A, characterized by a heavy chain corresponding to SEQ ID NO:13 and a light chain corresponding to SEQ ID NO:14. E. The antibody according to embodiment A, characterized by a heavy chain corresponding to SEQ ID NO:21 and a light chain corresponding to SEQ ID NO:14. F. The antibody according to embodiment A or C, which is chimeric. G. The antibody according to embodiment D or E, which is humanized. H. An immunoconjugate comprising the antibody according to any one of the preceding embodiments. I. The antibody according to any one of the preceding embodiments is used to treat IGLV3-21 R110 Use in patients with CLL who are positive for J. Use of the antibody according to embodiment 1, wherein the antibody is administered at 0.25-25 mg / kg 体重 dosage administration. K. Use of the antibody according to embodiment 1, wherein the antibody is administered at 1-20 mg / kg 体重 dosage administration. L. Use of the antibody according to embodiment 1, wherein the antibody is administered at 7-15 mg / kg 体重 dosage administration. M. Use of the antibody according to embodiment 1, wherein the antibody is administered at 8-12 mg / kg 体重 dosage administration. N. Use of the antibody according to any one of embodiments I to M, wherein the CLL is subgroup #2 CLL. O. A pharmaceutical composition comprising the antibody according to any one of embodiments A to H. P. A kit comprising the pharmaceutical composition according to embodiment O. Q. The kit or pharmaceutical composition according to any one of embodiments O to P for the treatment of IGLV3-21 R110 Use in patients with CLL who are positive for R. Use of the antibody according to any one of embodiments A to G in diagnosing CLL characterized by containing IGLV3-21 R110 BCR. S. Use of an antibody according to embodiment R, wherein the antibody is coupled to a detectable marker, or wherein a further antibody that specifically binds to the antibody and is coupled to a detectable marker is subsequently administered. BRIEF DESCRIPTION OF THE DRAWINGS
[0223] Figure 1 A to Figure 1 D shows the FACS FSC-SSC plot ( Figure 1 A. Figure 1 C), and mAb01-01-APC ( Figure 1 B. Figure 1 D, x-axis) and anti-IgM-PE ( Figure 1 B. Figure 1 D, y axis).
[0224] According to Example 4, Figure 1 A and Figure 1 The image in B was made from a 1:1 cell mixture containing IGHV3-21 / IGLV3-21 R110 BCR-positive TKO mouse cells and BCR-deficient TKO cells (cell mixture A) were stained with the above fluorescently labeled antibodies, while Figure 1 C and Figure 1 The image in D was made from a 1:1 cell mixture containing IGHV3-21 / IGLV3-21 G110 BCR-positive TKO mouse cells and TKO cells lacking BCR (cell mixture B).
[0225] from Figure 1 B and Figure 1 D It can be easily understood that almost half of the analyzed TKO cells were positively stained with the corresponding anti-IgM antibodies, indicating that they have BCR, which is consistent with the expression of BCR on the surface of about 50% of the TKO cells in the corresponding cell mixture. Figure 1 B and Figure 1 D, it is clear that the antibody "mAb01-01" of the present invention only recognizes the malignant variant of IGLV3-21 having the R110 mutation.
[0226] Figure 2 A to Figure 2 F shows a FACS graph of human PBMCs treated according to Example 6. Figure 2 A and Figure 2 D shows the FSC-SSC plot of the PBMCs, where Figure 1 A and Figure 1 C. A gate was set similarly for apparently live cells. Gated cells were plotted against anti-CD19-VioBright515 ( Figure 2 B and Figure 2 E), and anti-CD19-VioBright515 ( Figure 2 C and Figure 2 F). Figure 2 A to Figure 2 C depicts the positive diagnosis of IGHV4-39 / IGLV3-21 R110 - Analysis of BCR of B cells from patients' human PBMCs, and Figure 2 D to Figure 2 F depicts a patient whose CLL does not have IGHV3-21R110 - BCR characteristics (ie, non-IGLV3-21 R110 The same analysis was performed on human PBMCs from patients with CLL. Figure 2 B and Figure 2 D shows that CD5 / CD19 ++ B cells could be distinguished and in both patient samples ( Figure 2 C and Figure 2 F) Further comparison between mAb01-01 and IGLV3-21 showed that mAb01-01 selectively recognized only IGLV3-21 R110 Positive CLL B cells allow differentiation between CLL types.
[0227] Figure 3 Shown are comparative binding kinetics of antibodies HCO-LC0, HC6-LC6 and HC7-LC6 according to the present invention and according to Example 7. As can be seen, the three antibodies show essentially the same binding kinetics and have almost the same binding specificity at a concentration of 10 μg / ml.
[0228] Figure 4 Shown is a comparison of tissues stained with mAb01-01 and anti-IgG against mAb01-01 (left column) (sandwich assay) and the same tissue samples treated with anti-IgG alone (right column) according to Example 8. The top row shows IGLV3-21 R110 The corresponding results in tissue samples from positive CLL patients, while the lower row shows the results in healthy donor samples.
[0229] As can be seen from the comparison of the upper left picture with all the remaining pictures in the left column, mAb01-01 actively and selectively recognizes diseased B cells in the spleen of disease patients, and there is no cross-reaction with any healthy donor samples in the same tissue (spleen) and any other tissue type (skin, kidney, heart and brain). This shows that the antibodies of the invention are selective, safe and non-cross-reactive. The additional pictures in the right column show that the staining obtained in the upper left picture and the lack of staining in the lower pictures in the left column are not related to any background or other artifacts.
[0230] Figure 5 The absolute number of CLL cells in the spleen at the end of the experiment according to Example 9 is shown. In the experiment, artificially infected IGLV3-21 mice were treated with a (pharmaceutically inactive) control (Group A), an amount of 0.3 mg / kg body weight (Group B), an amount of 5 mg / kg body weight (Group C) and 10 mg / kg body weight (Group D) of mAb01-01. R110Xenograft mouse model of positive CLL. As can be seen from the figure, all treatments caused depletion of CLL cells in the spleen, and at 10 mg / kg, the depletion was very significant. This shows that the antibodies of the present invention do promote the growth of CLL cells with IGLV3-21. R110 Effective treatment of CLL characterized by positive BCR.
[0231] Figure 6 IGLV3-21 is shown R110 Schematic diagram of BCR-BCR homotypic interaction of light chain (as described by Minici et al.). Two adjacent BCRs are depicted, which have antigen binding subunits, transmembrane domains (TM), and signal transduction subunits (SU), which include heavy chains (HC) and light chains (LC), and the signal transduction subunits are composed of disulfide-linked heterodimers of Igα and Igβ proteins (CD79a / CD79b). The arginine mutated at position 110 (R) of one BCR interacts with the germline-encoded aspartic acid (D) at position 50 of the adjacent BCR. Further interactions between the two BCRs are mediated by germline-encoded amino acid residues, namely lysine (K) at position 16 and aspartic acid (D) at position 52.
[0232] Figure 7 IGLV3-21R is shown 110 Schematic diagram of . Figure 7 A: Exemplary IGLV3-21 of single letter code R110 (SEQ ID NO: 53). Amino acid residues involved in BCR-BCR homotypic interactions according to Minici et al. are marked in bold. Figure 7 B: Row 1: IGLV3-21 R110 Amino acid positions in . Row 2: Amino acid residues involved in BCR-BCR homotypic interactions according to Minici et al. Rows 3-5: Different variants of the YDSD motif are compared. Amino acids are depicted in a 3 letter code.
[0233] The present invention is further described by the following examples. These examples are provided only to illustrate the present invention by reference to specific embodiments. These examples, although illustrating certain specific aspects of the present invention, are not intended to limit or restrict the scope of the disclosed invention.
[0234] Unless otherwise described in detail, all examples were performed using standard techniques, which are well known and routine to those skilled in the art. The conventional molecular biology techniques of the following examples can be performed as described in standard laboratory manuals, such as Sambrook et al., 1989, supra. DETAILED DESCRIPTION
[0235] The preferred embodiments of the present invention are:
[0236] Example
[0237] Example 1
[0238] Production of mouse antibodies
[0239] Immunization and generation of hybridoma cell lines
[0240] By combining immunization of mice with a soluble form of BCR and selection of appropriate antibodies using a cell-based system, we developed a novel antibody against IGLV3-21. R110 In this cell system, the intact and functional BCR is presented membrane-bound.
[0241] First, a soluble BCR in IgG1 format had to be obtained for immunization of mice. Therefore, DNA segments encoding IGHV3-21 as an exemplary variable heavy chain (VH) and covering IGLV3-21 were synthesized by a contract manufacturer using standard procedures. R110 The DNA of the complete light chain (LC) of the IgG1 was obtained. They were then fused to the constant segment of mouse IgG1 by polymerase chain reaction (PCR) and cloned into a cytomegalovirus (CMV) vector. A human cell expression system based on HEK293T cells was used to express this IgG1 as described previously (SEQ ID NO: 49 for VH, and SEQ ID NO: 50 for LC), for example, in Rekombinante Lehrbuch and Kompendium für Studium und Praxis, 2.Auflage, SpringerVerlag 2019. A polyethyleneimine (PEI)-based protocol was used for transfection. After multiple passages, the supernatant was collected and the culture medium contained in the combined cell supernatant was purified using a protein G column. The purity and quality of soluble IgG1 were determined by Western blotting.
[0242] Thereafter, mice were immunized with a recombinantly produced soluble form of the BCR (see SEQ ID NOs: 49 and 50).
[0243] Then, immune cells with the desired specificity can be obtained from these mice and transformed into hybridoma cells by cell fusion. Secondly, a FACS screening method was performed using triple knockout cells (TKO; for knockout of genes λ5, RAG2, and SLP65) expressing various variants of the BCR to select cells that specifically target the IGLV3-21 gene. R110 Antibodies against the BCR.
[0244] Monoclonal antibodies were generated in mice and subsequently in hybridoma cells using standard procedures.
[0245] This method allowed the isolation of a unique monoclonal antibody "mab 01-01" (SEQ ID NO: 1 for the heavy chain, and SEQ ID NO: 2 for the light chain).
[0246] Selection of monoclonal antibodies
[0247] Positive clones are usually not screened by enzyme-linked immunosorbent assay (ELISA). Because the target structure is a membrane-bound receptor, it is crucial to verify the combination of potential antibodies in the cell system, that is, to retain the natural cell physiological state of this cell type to a great extent at the same time. First, fluorescence activated cell sorting (FACS) analysis is used to check the binding events of the supernatant collected in each group. For this purpose, different BCR variants are expressed on the surface of triple knockout (TKO) cell lines, which cannot express BCR itself.
[0248] The starting point for generating TKO cells is formed by transgenic mice whose genes λ5, RAG1 or RAG2 and SLP65 are knocked out accordingly (Dühren von Minden et al., 2012, Nature 489, p.309-313). The combination of RAG2 or RAG1 and λ5 knockout results in a blocked transition from the progenitor B cell stage to the pre-B cell stage, which is typically characterized by the beginning rearrangement of the VDJ segment of the heavy chain (HC). Therefore, they are progenitor B cells / pre-B cells. The activity of BCR can be measured by using inducible SLP65 reconstruction. For professionals, the production of such mice is known and belongs to the prior art. In order to obtain the cells, after killing the mice, the bone marrow of the femur is extracted from the mice. The cells obtained in this way are then cultured under conditions that promote the survival of progenitor B cells / pre-B cells (37°C, 7.5% CO2, Iscoves medium, 10% FCS, P / S, mouse IL7). After multiple passages, FACS sorting is performed for control purposes to sort the pro-B cells / pre-B cells and then return to culture. Markers for this purpose are known to the skilled person.
[0249] In order to reconstruct with 'BCR of interest', the corresponding sequence encoding VH is fused with human IgM constant segment by polymerase chain reaction (PCR), and heavy chain (HC) and light chain (LC) are cloned into corresponding expression vectors each with CMV promoter. These are introduced into packaging cell line (Phoenix cell line) by lipofection. After incubation for 36 hours, the viral supernatant is removed and used for centrifugal infection of TKO cells. Anti-IgM and anti-LC antibodies are used to determine BCR expression on FACS. For this purpose, some cells are taken and stained with 5 μl antibodies in PBS of 100 μL total volume respectively. Both the extraction of supernatant and the centrifugal infection of TKO are well-known procedures and are known to professionals. The knockout of RAG2 or RAG1 and λ5 ensures that only 'BCR of interest' is expressed on the surface.
[0250] In this way, two different BCR-expressing TKO cell lines were generated, one of which expressed membrane-bound IGHV3-21 / IGLV3-21 R110 To generate a second TKO cell line expressing BCR, we used a vector encoding IGLV3-21 R110 The arginine codon at position 110 of the DNA of the TKO cells was restored to the germline sequence by the well-known site-directed mutagenesis technique (see, e.g., Sambrook et al. 1989, supra). The resulting TKO cells expressed a BCR containing IGLV3-21 with a glycine at amino acid position 110 (IGLV3-21 G110 ). To generate a third control TKO cell line without BCR expression on its surface, centrifuge infection was performed with an empty expression vector. By reconstituting the cells with inducible SLP65, it is possible to characterize the expression of BCR functionality and thus verify the expression of IGHV3-21 / IGLV3-21 on the surface prior to selection. R110 The autonomous activity state of the BCR was determined using FACS analysis after induction of SLP65 and the use of Ca 2+ Ca-flux is measured using a Ca-dependent dye such as Indo-1. These methods are known to the skilled person (see M. Dühren-von Minden et al; Nature 2012). Using these cells as “targets”, FACS has now been used to identify cells that specifically bind to the IGLV3-21-containing R110 The first step is to identify the supernatant to which the antibody shows binding. In the first round of selection, supernatants from multiple clones are pooled and their binding profiles are examined. If a supernatant shows binding to IGHV3-21 / IGLV3-21 R110-BCR specific binding, a positive binding profile is given. Groups showing such profiles are isolated and the binding profiles of individual clones are characterized again during a second round of selection. Binding of the monoclonal antibodies is verified using a FACS binding assay using a fluorescently labeled anti-mouse IgG antibody.
[0251] This selection approach led to the identification of the antibody mAb01-01, which binds to IGHV3-21 / IGLV3-21 R110 BCR-positive TKO mouse cells, but not binding to IGHV3-21 / IGLV3-21 G110 BCR-positive TKO mouse cells.
[0252] Production of mouse antibodies
[0253] After identifying the preferred antibody by selection, mRNA was isolated from individual hybridoma clones, cDNA was produced and amplified by anchored PCR (Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination; Osterroth F, Alkan O, Mackensen A, Lindemann A, Fisch P, Skerra A, Veelken H, J Immunol Methods, October 29, 1999; 229 (1-2): 141-53). The sequence of the cDNA encoding the monoclonal antibody mAb01-01 was confirmed by Sanger sequencing (SEQ ID NO: 25 for HC nucleotides, SEQ ID NO: 26 for LC nucleotides) and placed in a vector suitable for expression in CHO cells.
[0254] Secondary anti-mouse IgG1-APC and IgG2-APC antibodies were used to verify the expression of mAb01-01 as IgG1 subtype. R110 TKO cells were stained with secondary antibody only in one batch and with mAb01-01 and secondary antibody in another batch. Subsequent FACS analysis confirmed that the antibody had been expressed as IgG1.
[0255] The specific monoclonal antibody mAb01-01 was sequenced. The following amino acid sequences were determined as depicted in Table 1: SEQ ID NO: 1 represents HC, SEQ ID NO: 2 represents LC, SEQ ID NO: 3 represents VH, and SEQ ID NO: 4 represents VL. The sequences corresponding to the complementarity determining regions (CDRs) of the heavy chain, i.e., H-CDR1, H-CDR2, and H-CDR3, are contained in SEQ ID NOs: 5, 6, and 7, while the sequences corresponding to the light chain CDRs, i.e., L-CDR1, L-CDR2, and L-CDR3, are contained in SEQ ID NOs: 8, 9, and 10.
[0256] Example 2
[0257] Production of chimeric antibodies
[0258] Chimeric antibodies were synthesized using mouse monoclonal antibody mAb01-01 VH and VL nucleotide sequences (SEQ ID NO: 27 represents VH nucleotides, and SEQ ID NO: 28 represents VL nucleotides). For this purpose, the VH sequence was fused to the constant domain sequence of the human IgG1 isotype (SEQ ID NO: 31 represents IgG1 constant nucleotides) by PCR, and the VL sequence was fused to the constant domain of the human IgK isotype (SEQ ID NO: 32 represents IgK constant nucleotides) and expressed using a CHO-based transient expression system. The cell culture supernatant containing the resulting antibody was clarified by centrifugation and filtration. The chimeric antibody was purified from the cell culture supernatant by affinity chromatography. The purity of the antibody was determined to be >95%, as determined by reducing and denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The protein content and concentration of the antibody were analyzed by size exclusion chromatography (SEC) in PBS buffer. All steps were performed using prior art equipment and techniques.
[0259] This approach produced the chimeric antibody "HCO-LC0", the sequence of which is summarized in Table 1.
[0260] Table 1: Sequences of murine and chimeric antibodies
[0261] Example 3
[0262] Generation of humanized antibodies
[0263] The humanization of mAb01-01 was performed by transplanting mouse CDRs into mature human antibody frameworks in silico using standard CDR transplantation techniques of Fusion Antibodies Plc, Belfast, N.Ireland. CDRx platform (Fusion Antibodies Plc, Belfast, N.Ireland) was used to maintain as many key residues as possible in the humanized variants that are important for VH / VL interfaces and canonical loop structures. Subsequently, the amino acid sequence of the humanized variants produced by the fusion antibody was converted to a nucleotide sequence using Geneiouse software (Geneious Prime 2, Auckland, New Zealand). The VH sequence of the constant domain sequence of human IgG1 isotype (SEQ ID NO: 31 represents IgG1 constant nucleotides) was fused to the VL sequence of the constant domain of human IgK isotype (SEQ ID NO: 32 represents IgK constant nucleotides) by PCR to produce 16 pairs of humanized heavy and light chains, and the gene sequence of the antibody was transiently expressed in Chinese hamster ovary cells (CHO). After batch culture, the expressed humanized antibodies were purified from the cell culture supernatant and analyzed as described in Example 2. Eight humanized antibodies were successfully produced as depicted in Table 2.
[0264] Table 2: Sequences of humanized antibodies
[0265] Example 4
[0266] mAb01-01 and IGLV3-21 R110 -BCR and IGLV3-21 G110 -Binding of BCRR TKO cells
[0267] The specificity of antibody mAb01-01 observed in the selection (Example 1) was verified in a FACS assay by using the antibody coupled to a fluorescent marker.
[0268] For this purpose, two cell mixtures, cell mixture A and cell mixture B, were prepared from three different TKO cell lines according to Example 1 and subsequently stained with mAb01-01-APC (mAb01-01 coupled to the fluorescent marker APC from Immunotools GmbH). For control, each batch was additionally stained with an anti-IgM antibody (anti-human IgM-PE, clone: MHM-88, BioLegend catalog number: 314508).
[0269] IGHV3-21 / IGLV3-21 were expressed in PBS buffer (Gibco, pH 7.2, catalog number 20012-019) at a 1:1 ratio. R110Cell mixture A was prepared from B cell receptor TKO cells and B cell receptor negative TKO cells (empty vector; control).
[0270] IGHV3-21 / IGLV3-21 expressed in PBS buffer at a 1:1 ratio G110 Cell mixture B was prepared from B cell receptor TKO cells and B cell receptor negative (empty vector; control) TKO cells.
[0271] Cells from cell mixture A or cell mixture B were plated at approximately 10 6 10 cells / FACS tube were suspended in antibody diluent (5 μg / ml mAb01-01-APC, 2 μg / ml anti-human IgM-PE, total volume 100 μl) in PBS buffer and incubated in the dark for 15 min at 4° C. Next, the cells were washed once with 1 ml of cold PBS buffer and resuspended in 200 μL of cold PBS buffer.
[0272] FACS analysis was performed using a MACSQuant analyzer 10 (Miltenyi Biotec BV & Co. KG; instrument calibrated as recommended by the manufacturer, flow rate: low, mixed sample: gentle mixing, mode, standard, absorption volume: 50 μL, sample volume: 200 μL). TKO-cells of cell mixture A or cell mixture B were gated on side scatter (SSC) and forward scatter (FSC), and gated TKO-cells were analyzed in anti-IgM-PE and mAb01-01-APC dot plots to calculate different TKO-cell populations using quadrant statistics.
[0273] like Figure 1 A to Figure 1 As shown in D, mAb01-01 and expression of human IGLV3-21 R110 -BCR binding to mouse TKO cells, but not to cells expressing human IGLV3-21 G110 -BCR binding of TKO mouse cells.
[0274] Example 5
[0275] Antibodies against IGLV3-21 R110 B cell receptor affinity
[0276] In order to determine whether the antibody contains IGLV3-21 R110The binding affinity of the B cell receptor of IgG1 was determined by transiently expressing a soluble recombinant version of the BCR (170.5 kDa; according to the sequence of SEQ ID NO:51 for HC and SEQ ID NO:52 for LC) as a monomeric human IgM in the 293-HEK cell line using the protocol described in Example 1, and binding to immobilized anti-IGLV3-21 was monitored by Bio-Layer Interferometry (BLI) on a Fortebio Octet instrument (Satorius). R110 Binding of antibodies.
[0277] First, anti-IGLV3-21 was captured by an indirect capture reagent, anti-human IgG Fc antibody. R110 Antibodies were immobilized on the biosensor and kinetic measurements were performed. Anti-IGLV3-21 was immobilized on the biosensor at a concentration of 0.01875 μg / ml. R110 Antibody loading to produce capture levels between 0.30nm and 0.34nm for anti-IGLV3-21 R110 Antibodies. A 9 nM BCR fragment solution was prepared in running buffer (PBS, 0.02% Tween20, 0.1% BSA, 0.05% sodium azide) and serially diluted at 1:3 to obtain 7 concentrations from 9 nM to 0.012 nM (9 nM, 3 nM, 1 nM, 0.333 nM, 0.111 nM, 0.037 nM and 0.012 nM). Anti-IGLV3-21 R110 The antibody capture biosensor was immersed in wells containing different concentrations of soluble BCR fragments for 900 s (association phase) followed by a 1200 s dissociation step in running buffer. The steps were performed at a constant shaking speed of 1000 rpm. All reagents were used as described by the manufacturer. Sensorgrams were generated after double reference correction (buffer and blank sensor) to compensate for the captured anti-IGLV3-21 R110 Both the natural dissociation of the antibody and the nonspecific binding of the soluble BCR fragment to the sensor surface. The dissociation rate constant (K D ) is based on the association (k a ) constant and dissociation rate (k d ) constant and were obtained by fitting the sensorgrams with a first-order 1:1 binding model using Fortebio data analysis software (Satorius).
[0278] As shown in Table 3, the chimeric antibody HCO-LC0 has a K of about 120 nM. D Values and soluble IGLV3-21 R110B cell receptor binding. Humanized antibodies HC6-LC6 and HC7-LC6 showed binding characteristics similar to those of chimeric antibody HC0-LC0, showing dissociation constants within 2-fold of chimeric antibody HC01 LC01. The K D For values, see Table 3.
[0279] Table 3: Soluble IGLV3-21 R110 B cell receptor monovalent K of chimeric antibody HCO-LC0 and humanized variants measured by Fortebio D Value and anti-IGLV3-21 R110 Antibody capture level
[0280] Example 6
[0281] Binding of the mouse antibody mAb01-01 to the cell surface of IGLV3-21R110-BCR positive human B-CLL cells
[0282] To determine the efficacy of mAb01-01 in IGLV3-21 R110 -B cell receptor-positive human CLL cells and non-IGLV3-21 R110 Binding characteristics on human B cells, binding tested by flow cytometry.
[0283] For this purpose, cryopreserved peripheral blood mononuclear cells (PBMCs) from two CLL patients were used. The CLL of one of these patients was characterized by the presence of IGLV3-21 R110 More specifically, CLL cells express IGLV3-21 R110 Combined BCR with IGHV4-39 heavy chain (IGHV4-39 / IGLV3-21 R110 -BCR). Another patient was diagnosed with non-IGLV3-21 R110 CLL. The cells can be isolated by density gradient centrifugation over Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB) using techniques known in the art, such as those described in A, Isolation of mononuclear cells and granulocytes from human blood, Scan. J. Clin. Lab. Invest. 1968, 21(Supplement 97): 77-89, PBMCs were isolated from heparinized venous blood.
[0284] The sample is thawed and resuspended in 5ml cell culture medium (RPMI, Gibco; 10% FCS, PAN-Biotec). The cells are centrifuged by 300g (Eppendorf centrifuge 5425R) and then resuspended in 1ml RPMI. Cell counts are obtained by using Neubauer Chamber. For staining, 1x10E6 cells are used and transferred to FACS tubes. 2μl anti-CD19 VioBright515 (Miltiny Biotech, Klon: REA675,), 2μl anti-CD5-PE-Vio770 (Miltenyi Biotec, Klon: REA782) and 5μl mAb01-01-APC (mAb01-01 is coupled to the fluorescent marker APC of Immunotools GmbH) are used in a total volume of 100μl PBS buffer to stain the cells, and incubate in the dark for 15min at 4°C. Next, wash the cells once with 1 ml of cold PBS buffer, resuspend in 200 μL of cold PBS buffer, and use BD LSRFortessa TM Analysis was performed by flow cytometry using a cell analyzer (BD bioscience). The instrument was calibrated as recommended by the manufacturer. Raw data were analyzed by using FlowJo-Software X (BD bioscience). The analysis gates were set as follows: Figure 2 shown.
[0285] like Figure 2 As shown, mAb01-01 binds exclusively to IGLV3-21 R110 Positive CLL B cells, but not bound to IGLV3-21 R110 More specifically, mAb01-01 recognized IGLV3-21, regardless of the nature of the heavy chain. R110 -BCR.
[0286] Example 7
[0287] Chimeric and humanized antibodies and IGLV3-21 R110 -BCR-positive mouse TKO cells cell surface binding feature
[0288] To compare the chimeric antibody and two humanized versions of the antibody with IGLV3-21 R110 -Specific binding of BCR to IGLV3-21 R110 -BCR mouse TKO cells (see Example 1) were incubated with different concentrations of antibodies HC0-LC0, HC6-LC6 and HC7-LC6 and analyzed by flow cytometry and sandwich assay setup. Controls were performed using a TKO-empty vector cell line (no surface BCR).
[0289] From each cell line, 7.5x10E6 cells were transferred to separate 15 ml bluecaps, centrifuged for 10 min (300 g at 4°C), and resuspended in 1.5 ml PBS (Gibco).
[0290] Staining was performed in 96-well plates (VWR, U-bottom, untreated). For each reaction, 2x10E5 cells were used. The experimental setup is shown in Table 4.
[0291] Table 4: Experimental setup for 96-well plates
[0292] To characterize the binding characteristics of different humanized variants, 10 different concentrations of each antibody in PBS (10 μg / ml, 5 μg / ml, 2.5 μg / ml, 0.625 μg / ml, 0.31 μg / ml, 0.16 μg / ml, 0.08 μg / ml, 0.04 μg / ml, 0 μg / ml) were used for staining in a total volume of 200 μl per well. Incubate in the dark at 4°C for 30 min. Then centrifuge 96 wells at 300g, 4°C (VWR, MEGA STAR 1.6R) for 10 min. Discard the supernatant and resuspend the cells in 100 μl of ice-cold PBS. For detection, a second antibody against human IgG1 labeled with APC was used at a final concentration of 10 μg / ml.
[0293] Incubate for 15 min at 4°C in the dark in a total volume of 200 μl / well, followed by an additional wash step with ice-cold PBS. Resuspend cells in 150 μl ice-cold PBS for collection. Analyze cells on MACS-Quant10 (Miltenyi Biotec), calibrated according to the manufacturer's instructions.
[0294] All IGLV3-21 was neutralized by subtracting the control cell values R110 -MFI (median fluorescence intensity) of BCR TKO measurements and plotted against the concentration of the antibody. The generated function demonstrated that all three antibodies were R110 -BCR showed a concentration-dependent increase. Figure 3 As shown, with increasing antibody concentration, the two humanized variants exhibited increasingly identical binding properties to the chimeric antibody and had almost identical binding specificity at latest at 10 μg / ml.
[0295] Example 8
[0296] Tissue cross-reactivity profile of mAb01-01
[0297] To characterize the binding of mAB01-01 to human CLL and healthy tissues in immunohistochemistry (IHC) experiments, cells expressing IGLV3-21 were cultured in vitro and in situ hybridization. R110 -BCR spleen tissue sections and healthy spleen, skin, kidney, heart and brain tissue sections were immunostained.
[0298] Before IHC, tissue sections were dewaxed and hydrated. In order to expose antigens, microwave treatment of citrate buffer pH 6.0 (9 ml citric acid (0.1 M) and 41 ml sodium citrate (0.1 M)) was performed. For this reason, the sections were boiled in bubbling citrate buffer for 15 min, then cooled at room temperature for 30 min, and then rinsed in PBS for 3x5 min. For IHC, slides were incubated with the first antibody at room temperature in a humidity chamber for 2 hours at a dilution of 1:200. As a control, the sections of all tissues were incubated under the same conditions without the first antibody. Thereafter, slides were washed in PBS for 3x5 min. The anti-IgG antibody (goat anti-mouse IgG (H+L)-HRP, Southern Biotech, catalog number 1036-05) coupled with horseradish peroxidase (HRP) as the second antibody was incubated in a humidification chamber for 1 hour at room temperature at a dilution of 1:10000. Subsequently, wash with PBS for 10 min, and use DAB substrate kit (#34065, Thermo Fisher) to detect the activity of HRP. DAB (3,3'-diaminobenzidine tetrahydrochloride) substrate is incubated for 15 min. Fluoromount-1 is used as a blocking agent. After 30 minutes, the evaluation is performed and an insoluble brown reaction product is shown at the site where the HRP-coupled anti-IgG antibody binds to the tissue.
[0299] like Figure 4 As shown, IGLV3-21 R110 - Positive staining can be observed in BCR positive spleen sections, so mAb01-01 has cross-reactivity when binding to human CLL tissue. In contrast, no staining was detected in healthy human tissue sections of spleen, skin, kidney, heart and brain. Therefore, mAb01-01 showed no cross-reactivity with healthy human tissue.
[0300] Example 9
[0301] Testing of anti-IGLV3-21R110-BCR antibodies in patient-derived xenograft models
[0302] To determine whether anti-IGLV3-21 R110To test the efficacy of the antibody, a patient-derived xenograft model was selected. For the dose-finding experiment, four groups were used, each with four NOD-scid IL2rg null (NSG) mice (Jackson ImmunoResearch, as prepared by Qi J et al.: An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies, Methods 2019, 154: 70-76): Group A: control group without antibody treatment Group B: dose 0.3 mg / kg body weight Group C: dose 5 mg / kg body weight Group D: dose 10 mg / kg body weight
[0303] Will come from IGLV3-21 R110 PMBS from patients with BCR were thawed and resuspended in PBS. T cells were isolated using Miltenyi CD3 beads (Miltenyi Biotec) according to the manufacturer's instructions. CD3 / CD28 dynabeads (Dynabeads for T cell expansion and activation) were used. TM Human T activator CD3 / CD28, catalog number 11161D, GIBCO) T cells were cultured and expanded for 7 days as described previously (Qi J et al., Methods, 2019s.a.).
[0304] After 7 days, activated T cells and PBMC (20×10 per mouse) were added to 6 CLL PBMC and 5×10 5 T cells) were injected intravenously into NSG mice. For treatment, mAb01-01 was given intraperitoneally at different doses starting from the 2nd week after implantation, twice a week for a total of 3 weeks. Mice were pretreated with 250 μl of human serum at the beginning of each week. Mice were sacrificed after 3 weeks of treatment. For analysis, spleens were isolated and human IGLV3-21 was analyzed by flow cytometry using mAb01-01 and antibodies against human CD45, CD5 and CD19 (CD5 IgG1 UCHT2, BioLegend; CD19 IgG1 HIB19, BD Biosciences; CD45 (human) IgG1H130 Invitrogen) R110 For flow cytometry, cells were collected by centrifugation and resuspended in ice-cold 0.1% (w / v) BSA in PBS (flow cytometry buffer).5 100 μL of each cell was dispensed into a V-bottom 96-well plate (Corning). Cells were first blocked on ice for 30 min with 5% (v / v) goat serum (Jackson ImmunoResearch) and then incubated with the specified antibodies as recommended by the manufacturer. Cells were incubated on ice in the dark for 30 min. Cells were then washed twice with ice-cold flow cytometry buffer, resuspended in 200 μL flow cytometry buffer, and analyzed using FACSCanto (BD Biosciences).
[0305] like Figure 5 As shown, treatment with mAb01-01 resulted in a decrease in tumor cell counts in all treated mice, and treatment with 10 mg / kg mAb01-01 greatly reduced tumor growth.
Claims
1. An antibody having The heavy chain amino acid sequence represented by SEQ ID NO: 1 and the light chain amino acid sequence represented by SEQ ID NO: 2, or The heavy chain amino acid sequence of SEQ ID NO: 11 and the light chain amino acid sequence of SEQ ID NO: 12; or An antibody comprising any combination of a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 and a variable light chain having a sequence selected from the list of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO:
19.
2. The antibody according to claim 1, Features The heavy chain corresponds to SEQ ID NO: 1 and the light chain corresponds to SEQ ID NO:
2.
3. The antibody according to claim 1, Features The heavy chain amino acid sequence of SEQ ID NO:11 and the light chain amino acid sequence of SEQ ID NO:
12.
4. The antibody according to claim 1, Features The heavy chain corresponds to SEQ ID NO:13 and the light chain corresponds to SEQ ID NO:
14.
5. The antibody according to claim 1, Features The heavy chain corresponds to SEQ ID NO:21 and the light chain corresponds to SEQ ID NO:
14.
6. The antibody according to claim 1 or 3, which is chimeric.
7. The antibody according to claims 4 and 5, which is humanized.
8. An immunoconjugate comprising the antibody according to any one of the preceding claims.
9. The antibody according to any one of the preceding claims in the treatment of IGLV3-21 R110 Use in patients with CLL who are positive for 10. The use of the antibody according to claim 9, wherein the antibody is administered at 0.25-25 mg / kg 体重 dosage administration.
11. The use of the antibody according to claim 9, wherein the antibody is administered at 1-20 mg / kg 体重 dosage administration.
12. The use of the antibody according to claim 9, wherein the antibody is administered at 7-15 mg / kg 体重 dosage administration.
13. The use of the antibody according to claim 9, wherein the antibody is administered at 8-12 mg / kg 体重 dosage administration.
14. Use of the antibody according to any one of claims 9 to 13, wherein the CLL is subgroup #2 CLL.
15. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier or excipient.
16. A kit comprising the pharmaceutical composition according to claim 15.
17. The kit or pharmaceutical composition according to claim 15 or 16 for treating IGLV3-21 R110 Use in patients with CLL who are positive for 18. Use of the antibody according to any one of claims 1 to 7 in the diagnosis of CLL characterized by containing IGLV3-21 R110 BCR.
19. Use of an antibody according to claim 18, wherein the antibody is coupled to a detectable marker.
20. Use of the antibody according to claim 18, wherein a further antibody is subsequently administered which specifically binds to the antibody according to any one of claims 1 to 7, and wherein such further antibody is coupled to a detectable marker.
